Appendix Table of Contents



Appendix Table of ContentsSUPPLEMENTARY METHODS………………………………………………………………...2SUPPLEMENTARY FIGURE…………………………………………………………………....3Figure A: Flowchart of population inclusion/exclusion criteria……...……………………….…..3Figure B: Study diagram illustrating treatment lines received ……………………………………4SUPPLEMENTARY TABLES………………………………………………...…………………5Table A: Conditions and Codes Used To Calculate CCI………………………..……………..….6Table B: Healthcare Common Procedure Coding System (HCPCS) codes and National Drug Codes (NDC) for DLBCL treatment per NCCN guidelines.…………………………………….. 34Table C: Codes for HSCT (includes autologous and allogeneic transplantations)………………42References……………………………………………………………………………………….43SUPPLEMENTARY METHODS MeasuresComorbidities during the baseline period (defined as the period 12 months prior to initial diagnosis of DLBCL) were assessed using the Quan-adapted CCI and categorized into 3 groups (0, 1–2, ≥3) PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5RdWFuPC9BdXRob3I+PFllYXI+MjAwNTwvWWVhcj48UmVj

TnVtPjQzPC9SZWNOdW0+PERpc3BsYXlUZXh0PlsxLCAyLCAzLCA0XTwvRGlzcGxheVRleHQ+PHJl

Y29yZD48cmVjLW51bWJlcj40MzwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJF

TiIgZGItaWQ9IjVwZHdydjk5M3hkcnhoZXB0NXh2ZWVkNHJ4ZXd4YXd0MHZ4eCIgdGltZXN0YW1w

PSIxNTQwODI0ODA3Ij40Mzwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3Vy

bmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+

UXVhbiwgSC48L2F1dGhvcj48YXV0aG9yPlN1bmRhcmFyYWphbiwgVi48L2F1dGhvcj48YXV0aG9y

PkhhbGZvbiwgUC48L2F1dGhvcj48YXV0aG9yPkZvbmcsIEEuPC9hdXRob3I+PGF1dGhvcj5CdXJu

YW5kLCBCLjwvYXV0aG9yPjxhdXRob3I+THV0aGksIEouIEMuPC9hdXRob3I+PGF1dGhvcj5TYXVu

ZGVycywgTC4gRC48L2F1dGhvcj48YXV0aG9yPkJlY2ssIEMuIEEuPC9hdXRob3I+PGF1dGhvcj5G

ZWFzYnksIFQuIEUuPC9hdXRob3I+PGF1dGhvcj5HaGFsaSwgVy4gQS48L2F1dGhvcj48L2F1dGhv

cnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5EZXBhcnRtZW50IG9mIENvbW11bml0eSBI

ZWFsdGggU2NpZW5jZXMsIFVuaXZlcnNpdHkgb2YgQ2FsZ2FyeSwgQ2FsZ2FyeSwgQWxiZXJ0YSwg

Q2FuYWRhLiBocXVhbkB1Y2FsZ2FyeS5jYTwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxlPkNv

ZGluZyBhbGdvcml0aG1zIGZvciBkZWZpbmluZyBjb21vcmJpZGl0aWVzIGluIElDRC05LUNNIGFu

ZCBJQ0QtMTAgYWRtaW5pc3RyYXRpdmUgZGF0YTwvdGl0bGU+PHNlY29uZGFyeS10aXRsZT5NZWQg

Q2FyZTwvc2Vjb25kYXJ5LXRpdGxlPjxhbHQtdGl0bGU+TWVkaWNhbCBjYXJlPC9hbHQtdGl0bGU+

PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+TWVkIENhcmU8L2Z1bGwtdGl0bGU+PGFi

YnItMT5NZWRpY2FsIGNhcmU8L2FiYnItMT48L3BlcmlvZGljYWw+PGFsdC1wZXJpb2RpY2FsPjxm

dWxsLXRpdGxlPk1lZCBDYXJlPC9mdWxsLXRpdGxlPjxhYmJyLTE+TWVkaWNhbCBjYXJlPC9hYmJy

LTE+PC9hbHQtcGVyaW9kaWNhbD48cGFnZXM+MTEzMC05PC9wYWdlcz48dm9sdW1lPjQzPC92b2x1

bWU+PG51bWJlcj4xMTwvbnVtYmVyPjxlZGl0aW9uPjIwMDUvMTAvMTU8L2VkaXRpb24+PGtleXdv

cmRzPjxrZXl3b3JkPipBbGdvcml0aG1zPC9rZXl3b3JkPjxrZXl3b3JkPkNhbmFkYS9lcGlkZW1p

b2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+KkNvbW9yYmlkaXR5PC9rZXl3b3JkPjxrZXl3b3JkPkRp

c2Vhc2UvY2xhc3NpZmljYXRpb248L2tleXdvcmQ+PGtleXdvcmQ+RmVtYWxlPC9rZXl3b3JkPjxr

ZXl3b3JkPkZvcm1zIGFuZCBSZWNvcmRzIENvbnRyb2wvKm1ldGhvZHM8L2tleXdvcmQ+PGtleXdv

cmQ+SG9zcGl0YWwgTW9ydGFsaXR5PC9rZXl3b3JkPjxrZXl3b3JkPkh1bWFuczwva2V5d29yZD48

a2V5d29yZD4qSW50ZXJuYXRpb25hbCBDbGFzc2lmaWNhdGlvbiBvZiBEaXNlYXNlczwva2V5d29y

ZD48a2V5d29yZD5NYWxlPC9rZXl3b3JkPjxrZXl3b3JkPk1lZGljYWwgUmVjb3Jkcy9jbGFzc2lm

aWNhdGlvbjwva2V5d29yZD48a2V5d29yZD5NaWRkbGUgQWdlZDwva2V5d29yZD48a2V5d29yZD5N

b2RlbHMsIFN0YXRpc3RpY2FsPC9rZXl3b3JkPjxrZXl3b3JkPlJpc2sgQWRqdXN0bWVudDwva2V5

d29yZD48L2tleXdvcmRzPjxkYXRlcz48eWVhcj4yMDA1PC95ZWFyPjxwdWItZGF0ZXM+PGRhdGU+

Tm92PC9kYXRlPjwvcHViLWRhdGVzPjwvZGF0ZXM+PGlzYm4+MDAyNS03MDc5IChQcmludCkmI3hE

OzAwMjUtNzA3OTwvaXNibj48YWNjZXNzaW9uLW51bT4xNjIyNDMwNzwvYWNjZXNzaW9uLW51bT48

dXJscz48L3VybHM+PHJlbW90ZS1kYXRhYmFzZS1wcm92aWRlcj5OTE08L3JlbW90ZS1kYXRhYmFz

ZS1wcm92aWRlcj48bGFuZ3VhZ2U+ZW5nPC9sYW5ndWFnZT48L3JlY29yZD48L0NpdGU+PENpdGU+

PEF1dGhvcj5RdWFuPC9BdXRob3I+PFllYXI+MjAxMTwvWWVhcj48UmVjTnVtPjQ0PC9SZWNOdW0+

PHJlY29yZD48cmVjLW51bWJlcj40NDwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBw

PSJFTiIgZGItaWQ9IjVwZHdydjk5M3hkcnhoZXB0NXh2ZWVkNHJ4ZXd4YXd0MHZ4eCIgdGltZXN0

YW1wPSIxNTQwODI0ODcwIj40NDwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJK

b3VybmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRo

b3I+UXVhbiwgSC48L2F1dGhvcj48YXV0aG9yPkxpLCBCLjwvYXV0aG9yPjxhdXRob3I+Q291cmlz

LCBDLiBNLjwvYXV0aG9yPjxhdXRob3I+RnVzaGltaSwgSy48L2F1dGhvcj48YXV0aG9yPkdyYWhh

bSwgUC48L2F1dGhvcj48YXV0aG9yPkhpZGVyLCBQLjwvYXV0aG9yPjxhdXRob3I+SmFudWVsLCBK

LiBNLjwvYXV0aG9yPjxhdXRob3I+U3VuZGFyYXJhamFuLCBWLjwvYXV0aG9yPjwvYXV0aG9ycz48

L2NvbnRyaWJ1dG9ycz48YXV0aC1hZGRyZXNzPkRlcGFydG1lbnQgb2YgQ29tbXVuaXR5IEhlYWx0

aCBTY2llbmNlcywgRmFjdWx0eSBvZiBNZWRpY2luZSwgVW5pdmVyc2l0eSBvZiBDYWxnYXJ5LCAz

MjgwIEhvc3BpdGFsIERyaXZlIE5XLCBDYWxnYXJ5LCBBbGJlcnRhLCBDYW5hZGEgVDJOIDRaNi4g

aHF1YW5AdWNhbGdhcnkuY2E8L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5VcGRhdGluZyBh

bmQgdmFsaWRhdGluZyB0aGUgQ2hhcmxzb24gY29tb3JiaWRpdHkgaW5kZXggYW5kIHNjb3JlIGZv

ciByaXNrIGFkanVzdG1lbnQgaW4gaG9zcGl0YWwgZGlzY2hhcmdlIGFic3RyYWN0cyB1c2luZyBk

YXRhIGZyb20gNiBjb3VudHJpZXM8L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+QW0gSiBFcGlkZW1p

b2w8L3NlY29uZGFyeS10aXRsZT48YWx0LXRpdGxlPkFtZXJpY2FuIGpvdXJuYWwgb2YgZXBpZGVt

aW9sb2d5PC9hbHQtdGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+QW0gSiBF

cGlkZW1pb2w8L2Z1bGwtdGl0bGU+PGFiYnItMT5BbWVyaWNhbiBqb3VybmFsIG9mIGVwaWRlbWlv

bG9neTwvYWJici0xPjwvcGVyaW9kaWNhbD48YWx0LXBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+QW0g

SiBFcGlkZW1pb2w8L2Z1bGwtdGl0bGU+PGFiYnItMT5BbWVyaWNhbiBqb3VybmFsIG9mIGVwaWRl

bWlvbG9neTwvYWJici0xPjwvYWx0LXBlcmlvZGljYWw+PHBhZ2VzPjY3Ni04MjwvcGFnZXM+PHZv

bHVtZT4xNzM8L3ZvbHVtZT48bnVtYmVyPjY8L251bWJlcj48ZWRpdGlvbj4yMDExLzAyLzE5PC9l

ZGl0aW9uPjxrZXl3b3Jkcz48a2V5d29yZD5BZHVsdDwva2V5d29yZD48a2V5d29yZD5BZ2UgRmFj

dG9yczwva2V5d29yZD48a2V5d29yZD5BZ2VkPC9rZXl3b3JkPjxrZXl3b3JkPkF1c3RyYWxpYS9l

cGlkZW1pb2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+Q2FuYWRhL2VwaWRlbWlvbG9neTwva2V5d29y

ZD48a2V5d29yZD4qQ29tb3JiaWRpdHk8L2tleXdvcmQ+PGtleXdvcmQ+Q29zdCBvZiBJbGxuZXNz

PC9rZXl3b3JkPjxrZXl3b3JkPkRpYWdub3Npcy1SZWxhdGVkIEdyb3Vwcy9zdGF0aXN0aWNzICZh

bXA7IG51bWVyaWNhbCBkYXRhPC9rZXl3b3JkPjxrZXl3b3JkPkZlbWFsZTwva2V5d29yZD48a2V5

d29yZD5GcmFuY2UvZXBpZGVtaW9sb2d5PC9rZXl3b3JkPjxrZXl3b3JkPipIb3NwaXRhbCBNb3J0

YWxpdHk8L2tleXdvcmQ+PGtleXdvcmQ+SHVtYW5zPC9rZXl3b3JkPjxrZXl3b3JkPkphcGFuL2Vw

aWRlbWlvbG9neTwva2V5d29yZD48a2V5d29yZD5NYWxlPC9rZXl3b3JkPjxrZXl3b3JkPk1pZGRs

ZSBBZ2VkPC9rZXl3b3JkPjxrZXl3b3JkPk1vcnRhbGl0eTwva2V5d29yZD48a2V5d29yZD5OZXcg

WmVhbGFuZC9lcGlkZW1pb2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+UGF0aWVudCBEaXNjaGFyZ2Uv

KnN0YXRpc3RpY3MgJmFtcDsgbnVtZXJpY2FsIGRhdGE8L2tleXdvcmQ+PGtleXdvcmQ+UHJvcG9y

dGlvbmFsIEhhemFyZHMgTW9kZWxzPC9rZXl3b3JkPjxrZXl3b3JkPlJpc2sgQWRqdXN0bWVudDwv

a2V5d29yZD48a2V5d29yZD5TZXggRmFjdG9yczwva2V5d29yZD48a2V5d29yZD5Td2l0emVybGFu

ZC9lcGlkZW1pb2xvZ3k8L2tleXdvcmQ+PC9rZXl3b3Jkcz48ZGF0ZXM+PHllYXI+MjAxMTwveWVh

cj48cHViLWRhdGVzPjxkYXRlPk1hciAxNTwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2Ju

PjAwMDItOTI2MjwvaXNibj48YWNjZXNzaW9uLW51bT4yMTMzMDMzOTwvYWNjZXNzaW9uLW51bT48

dXJscz48L3VybHM+PGVsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjEwLjEwOTMvYWplL2t3cTQzMzwv

ZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+PHJlbW90ZS1kYXRhYmFzZS1wcm92aWRlcj5OTE08L3Jl

bW90ZS1kYXRhYmFzZS1wcm92aWRlcj48bGFuZ3VhZ2U+ZW5nPC9sYW5ndWFnZT48L3JlY29yZD48

L0NpdGU+PENpdGU+PEF1dGhvcj5DaGFybHNvbjwvQXV0aG9yPjxZZWFyPjE5ODc8L1llYXI+PFJl

Y051bT40NjwvUmVjTnVtPjxyZWNvcmQ+PHJlYy1udW1iZXI+NDY8L3JlYy1udW1iZXI+PGZvcmVp

Z24ta2V5cz48a2V5IGFwcD0iRU4iIGRiLWlkPSI1cGR3cnY5OTN4ZHJ4aGVwdDV4dmVlZDRyeGV3

eGF3dDB2eHgiIHRpbWVzdGFtcD0iMTU0MjcwMDAxMyI+NDY8L2tleT48L2ZvcmVpZ24ta2V5cz48

cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9y

cz48YXV0aG9ycz48YXV0aG9yPkNoYXJsc29uLCBNLiBFLjwvYXV0aG9yPjxhdXRob3I+UG9tcGVp

LCBQLjwvYXV0aG9yPjxhdXRob3I+QWxlcywgSy4gTC48L2F1dGhvcj48YXV0aG9yPk1hY0tlbnpp

ZSwgQy4gUi48L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PHRpdGxlcz48dGl0bGU+

QSBuZXcgbWV0aG9kIG9mIGNsYXNzaWZ5aW5nIHByb2dub3N0aWMgY29tb3JiaWRpdHkgaW4gbG9u

Z2l0dWRpbmFsIHN0dWRpZXM6IGRldmVsb3BtZW50IGFuZCB2YWxpZGF0aW9uPC90aXRsZT48c2Vj

b25kYXJ5LXRpdGxlPkogQ2hyb25pYyBEaXM8L3NlY29uZGFyeS10aXRsZT48YWx0LXRpdGxlPkpv

dXJuYWwgb2YgY2hyb25pYyBkaXNlYXNlczwvYWx0LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2RpY2Fs

PjxmdWxsLXRpdGxlPkogQ2hyb25pYyBEaXM8L2Z1bGwtdGl0bGU+PGFiYnItMT5Kb3VybmFsIG9m

IGNocm9uaWMgZGlzZWFzZXM8L2FiYnItMT48L3BlcmlvZGljYWw+PGFsdC1wZXJpb2RpY2FsPjxm

dWxsLXRpdGxlPkogQ2hyb25pYyBEaXM8L2Z1bGwtdGl0bGU+PGFiYnItMT5Kb3VybmFsIG9mIGNo

cm9uaWMgZGlzZWFzZXM8L2FiYnItMT48L2FsdC1wZXJpb2RpY2FsPjxwYWdlcz4zNzMtODM8L3Bh

Z2VzPjx2b2x1bWU+NDA8L3ZvbHVtZT48bnVtYmVyPjU8L251bWJlcj48ZWRpdGlvbj4xOTg3LzAx

LzAxPC9lZGl0aW9uPjxrZXl3b3Jkcz48a2V5d29yZD5BY3R1YXJpYWwgQW5hbHlzaXM8L2tleXdv

cmQ+PGtleXdvcmQ+QWdlIEZhY3RvcnM8L2tleXdvcmQ+PGtleXdvcmQ+QnJlYXN0IE5lb3BsYXNt

cy9lcGlkZW1pb2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+KkVwaWRlbWlvbG9naWMgTWV0aG9kczwv

a2V5d29yZD48a2V5d29yZD5GZW1hbGU8L2tleXdvcmQ+PGtleXdvcmQ+Rm9sbG93LVVwIFN0dWRp

ZXM8L2tleXdvcmQ+PGtleXdvcmQ+SHVtYW5zPC9rZXl3b3JkPjxrZXl3b3JkPipMb25naXR1ZGlu

YWwgU3R1ZGllczwva2V5d29yZD48a2V5d29yZD4qTW9yYmlkaXR5PC9rZXl3b3JkPjxrZXl3b3Jk

Pk5ldyBZb3JrIENpdHk8L2tleXdvcmQ+PGtleXdvcmQ+UHJvZ25vc2lzPC9rZXl3b3JkPjxrZXl3

b3JkPlByb3NwZWN0aXZlIFN0dWRpZXM8L2tleXdvcmQ+PGtleXdvcmQ+Umlzazwva2V5d29yZD48

L2tleXdvcmRzPjxkYXRlcz48eWVhcj4xOTg3PC95ZWFyPjwvZGF0ZXM+PGlzYm4+MDAyMS05Njgx

IChQcmludCkmI3hEOzAwMjEtOTY4MTwvaXNibj48YWNjZXNzaW9uLW51bT4zNTU4NzE2PC9hY2Nl

c3Npb24tbnVtPjx1cmxzPjwvdXJscz48cmVtb3RlLWRhdGFiYXNlLXByb3ZpZGVyPk5MTTwvcmVt

b3RlLWRhdGFiYXNlLXByb3ZpZGVyPjxsYW5ndWFnZT5lbmc8L2xhbmd1YWdlPjwvcmVjb3JkPjwv

Q2l0ZT48Q2l0ZT48QXV0aG9yPktoYW48L0F1dGhvcj48WWVhcj4yMDEwPC9ZZWFyPjxSZWNOdW0+

NDc8L1JlY051bT48cmVjb3JkPjxyZWMtbnVtYmVyPjQ3PC9yZWMtbnVtYmVyPjxmb3JlaWduLWtl

eXM+PGtleSBhcHA9IkVOIiBkYi1pZD0iNXBkd3J2OTkzeGRyeGhlcHQ1eHZlZWQ0cnhld3hhd3Qw

dnh4IiB0aW1lc3RhbXA9IjE1NDI3MDAxMTEiPjQ3PC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10

eXBlIG5hbWU9IkpvdXJuYWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1

dGhvcnM+PGF1dGhvcj5LaGFuLCBOLiBGLjwvYXV0aG9yPjxhdXRob3I+UGVyZXJhLCBSLjwvYXV0

aG9yPjxhdXRob3I+SGFycGVyLCBTLjwvYXV0aG9yPjxhdXRob3I+Um9zZSwgUC4gVy48L2F1dGhv

cj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5EZXBhcnRtZW50IG9mIFBy

aW1hcnkgSGVhbHRoIENhcmUsIFVuaXZlcnNpdHkgb2YgT3hmb3JkLCBPbGQgUm9hZCBDYW1wdXMs

IE94Zm9yZCBPWDMgN0xGLCBVSy4gbmFkYS5raGFuQGRwaHBjLm94LmFjLnVrPC9hdXRoLWFkZHJl

c3M+PHRpdGxlcz48dGl0bGU+QWRhcHRhdGlvbiBhbmQgdmFsaWRhdGlvbiBvZiB0aGUgQ2hhcmxz

b24gSW5kZXggZm9yIFJlYWQvT1hNSVMgY29kZWQgZGF0YWJhc2VzPC90aXRsZT48c2Vjb25kYXJ5

LXRpdGxlPkJNQyBGYW0gUHJhY3Q8L3NlY29uZGFyeS10aXRsZT48YWx0LXRpdGxlPkJNQyBmYW1p

bHkgcHJhY3RpY2U8L2FsdC10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5C

TUMgRmFtIFByYWN0PC9mdWxsLXRpdGxlPjxhYmJyLTE+Qk1DIGZhbWlseSBwcmFjdGljZTwvYWJi

ci0xPjwvcGVyaW9kaWNhbD48YWx0LXBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+Qk1DIEZhbSBQcmFj

dDwvZnVsbC10aXRsZT48YWJici0xPkJNQyBmYW1pbHkgcHJhY3RpY2U8L2FiYnItMT48L2FsdC1w

ZXJpb2RpY2FsPjxwYWdlcz4xPC9wYWdlcz48dm9sdW1lPjExPC92b2x1bWU+PGVkaXRpb24+MjAx

MC8wMS8wNzwvZWRpdGlvbj48a2V5d29yZHM+PGtleXdvcmQ+Q2xpbmljYWwgTWVkaWNpbmUvY2xh

c3NpZmljYXRpb248L2tleXdvcmQ+PGtleXdvcmQ+KkNvbW9yYmlkaXR5PC9rZXl3b3JkPjxrZXl3

b3JkPkRhdGFiYXNlcywgRmFjdHVhbDwva2V5d29yZD48a2V5d29yZD4qRmFtaWx5IFByYWN0aWNl

PC9rZXl3b3JkPjxrZXl3b3JkPkhpc3RvcnksIDIwdGggQ2VudHVyeTwva2V5d29yZD48a2V5d29y

ZD5IdW1hbnM8L2tleXdvcmQ+PGtleXdvcmQ+TG9naXN0aWMgTW9kZWxzPC9rZXl3b3JkPjxrZXl3

b3JkPipNb3J0YWxpdHk8L2tleXdvcmQ+PGtleXdvcmQ+UHJpbWFyeSBIZWFsdGggQ2FyZS9jbGFz

c2lmaWNhdGlvbjwva2V5d29yZD48a2V5d29yZD5Qcm9wb3J0aW9uYWwgSGF6YXJkcyBNb2RlbHM8

L2tleXdvcmQ+PGtleXdvcmQ+U29mdHdhcmU8L2tleXdvcmQ+PGtleXdvcmQ+KlZvY2FidWxhcnks

IENvbnRyb2xsZWQvaGlzdG9yeTwva2V5d29yZD48L2tleXdvcmRzPjxkYXRlcz48eWVhcj4yMDEw

PC95ZWFyPjxwdWItZGF0ZXM+PGRhdGU+SmFuIDU8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48

aXNibj4xNDcxLTIyOTY8L2lzYm4+PGFjY2Vzc2lvbi1udW0+MjAwNTExMTA8L2FjY2Vzc2lvbi1u

dW0+PHVybHM+PC91cmxzPjxjdXN0b20yPlBNQzI4MjA0Njg8L2N1c3RvbTI+PGVsZWN0cm9uaWMt

cmVzb3VyY2UtbnVtPjEwLjExODYvMTQ3MS0yMjk2LTExLTE8L2VsZWN0cm9uaWMtcmVzb3VyY2Ut

bnVtPjxyZW1vdGUtZGF0YWJhc2UtcHJvdmlkZXI+TkxNPC9yZW1vdGUtZGF0YWJhc2UtcHJvdmlk

ZXI+PGxhbmd1YWdlPmVuZzwvbGFuZ3VhZ2U+PC9yZWNvcmQ+PC9DaXRlPjwvRW5kTm90ZT4A

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5RdWFuPC9BdXRob3I+PFllYXI+MjAwNTwvWWVhcj48UmVj

TnVtPjQzPC9SZWNOdW0+PERpc3BsYXlUZXh0PlsxLCAyLCAzLCA0XTwvRGlzcGxheVRleHQ+PHJl

Y29yZD48cmVjLW51bWJlcj40MzwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJF

TiIgZGItaWQ9IjVwZHdydjk5M3hkcnhoZXB0NXh2ZWVkNHJ4ZXd4YXd0MHZ4eCIgdGltZXN0YW1w

PSIxNTQwODI0ODA3Ij40Mzwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3Vy

bmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+

UXVhbiwgSC48L2F1dGhvcj48YXV0aG9yPlN1bmRhcmFyYWphbiwgVi48L2F1dGhvcj48YXV0aG9y

PkhhbGZvbiwgUC48L2F1dGhvcj48YXV0aG9yPkZvbmcsIEEuPC9hdXRob3I+PGF1dGhvcj5CdXJu

YW5kLCBCLjwvYXV0aG9yPjxhdXRob3I+THV0aGksIEouIEMuPC9hdXRob3I+PGF1dGhvcj5TYXVu

ZGVycywgTC4gRC48L2F1dGhvcj48YXV0aG9yPkJlY2ssIEMuIEEuPC9hdXRob3I+PGF1dGhvcj5G

ZWFzYnksIFQuIEUuPC9hdXRob3I+PGF1dGhvcj5HaGFsaSwgVy4gQS48L2F1dGhvcj48L2F1dGhv

cnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5EZXBhcnRtZW50IG9mIENvbW11bml0eSBI

ZWFsdGggU2NpZW5jZXMsIFVuaXZlcnNpdHkgb2YgQ2FsZ2FyeSwgQ2FsZ2FyeSwgQWxiZXJ0YSwg

Q2FuYWRhLiBocXVhbkB1Y2FsZ2FyeS5jYTwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxlPkNv

ZGluZyBhbGdvcml0aG1zIGZvciBkZWZpbmluZyBjb21vcmJpZGl0aWVzIGluIElDRC05LUNNIGFu

ZCBJQ0QtMTAgYWRtaW5pc3RyYXRpdmUgZGF0YTwvdGl0bGU+PHNlY29uZGFyeS10aXRsZT5NZWQg

Q2FyZTwvc2Vjb25kYXJ5LXRpdGxlPjxhbHQtdGl0bGU+TWVkaWNhbCBjYXJlPC9hbHQtdGl0bGU+

PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+TWVkIENhcmU8L2Z1bGwtdGl0bGU+PGFi

YnItMT5NZWRpY2FsIGNhcmU8L2FiYnItMT48L3BlcmlvZGljYWw+PGFsdC1wZXJpb2RpY2FsPjxm

dWxsLXRpdGxlPk1lZCBDYXJlPC9mdWxsLXRpdGxlPjxhYmJyLTE+TWVkaWNhbCBjYXJlPC9hYmJy

LTE+PC9hbHQtcGVyaW9kaWNhbD48cGFnZXM+MTEzMC05PC9wYWdlcz48dm9sdW1lPjQzPC92b2x1

bWU+PG51bWJlcj4xMTwvbnVtYmVyPjxlZGl0aW9uPjIwMDUvMTAvMTU8L2VkaXRpb24+PGtleXdv

cmRzPjxrZXl3b3JkPipBbGdvcml0aG1zPC9rZXl3b3JkPjxrZXl3b3JkPkNhbmFkYS9lcGlkZW1p

b2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+KkNvbW9yYmlkaXR5PC9rZXl3b3JkPjxrZXl3b3JkPkRp

c2Vhc2UvY2xhc3NpZmljYXRpb248L2tleXdvcmQ+PGtleXdvcmQ+RmVtYWxlPC9rZXl3b3JkPjxr

ZXl3b3JkPkZvcm1zIGFuZCBSZWNvcmRzIENvbnRyb2wvKm1ldGhvZHM8L2tleXdvcmQ+PGtleXdv

cmQ+SG9zcGl0YWwgTW9ydGFsaXR5PC9rZXl3b3JkPjxrZXl3b3JkPkh1bWFuczwva2V5d29yZD48

a2V5d29yZD4qSW50ZXJuYXRpb25hbCBDbGFzc2lmaWNhdGlvbiBvZiBEaXNlYXNlczwva2V5d29y

ZD48a2V5d29yZD5NYWxlPC9rZXl3b3JkPjxrZXl3b3JkPk1lZGljYWwgUmVjb3Jkcy9jbGFzc2lm

aWNhdGlvbjwva2V5d29yZD48a2V5d29yZD5NaWRkbGUgQWdlZDwva2V5d29yZD48a2V5d29yZD5N

b2RlbHMsIFN0YXRpc3RpY2FsPC9rZXl3b3JkPjxrZXl3b3JkPlJpc2sgQWRqdXN0bWVudDwva2V5

d29yZD48L2tleXdvcmRzPjxkYXRlcz48eWVhcj4yMDA1PC95ZWFyPjxwdWItZGF0ZXM+PGRhdGU+

Tm92PC9kYXRlPjwvcHViLWRhdGVzPjwvZGF0ZXM+PGlzYm4+MDAyNS03MDc5IChQcmludCkmI3hE

OzAwMjUtNzA3OTwvaXNibj48YWNjZXNzaW9uLW51bT4xNjIyNDMwNzwvYWNjZXNzaW9uLW51bT48

dXJscz48L3VybHM+PHJlbW90ZS1kYXRhYmFzZS1wcm92aWRlcj5OTE08L3JlbW90ZS1kYXRhYmFz

ZS1wcm92aWRlcj48bGFuZ3VhZ2U+ZW5nPC9sYW5ndWFnZT48L3JlY29yZD48L0NpdGU+PENpdGU+

PEF1dGhvcj5RdWFuPC9BdXRob3I+PFllYXI+MjAxMTwvWWVhcj48UmVjTnVtPjQ0PC9SZWNOdW0+

PHJlY29yZD48cmVjLW51bWJlcj40NDwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBw

PSJFTiIgZGItaWQ9IjVwZHdydjk5M3hkcnhoZXB0NXh2ZWVkNHJ4ZXd4YXd0MHZ4eCIgdGltZXN0

YW1wPSIxNTQwODI0ODcwIj40NDwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJK

b3VybmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRo

b3I+UXVhbiwgSC48L2F1dGhvcj48YXV0aG9yPkxpLCBCLjwvYXV0aG9yPjxhdXRob3I+Q291cmlz

LCBDLiBNLjwvYXV0aG9yPjxhdXRob3I+RnVzaGltaSwgSy48L2F1dGhvcj48YXV0aG9yPkdyYWhh

bSwgUC48L2F1dGhvcj48YXV0aG9yPkhpZGVyLCBQLjwvYXV0aG9yPjxhdXRob3I+SmFudWVsLCBK

LiBNLjwvYXV0aG9yPjxhdXRob3I+U3VuZGFyYXJhamFuLCBWLjwvYXV0aG9yPjwvYXV0aG9ycz48

L2NvbnRyaWJ1dG9ycz48YXV0aC1hZGRyZXNzPkRlcGFydG1lbnQgb2YgQ29tbXVuaXR5IEhlYWx0

aCBTY2llbmNlcywgRmFjdWx0eSBvZiBNZWRpY2luZSwgVW5pdmVyc2l0eSBvZiBDYWxnYXJ5LCAz

MjgwIEhvc3BpdGFsIERyaXZlIE5XLCBDYWxnYXJ5LCBBbGJlcnRhLCBDYW5hZGEgVDJOIDRaNi4g

aHF1YW5AdWNhbGdhcnkuY2E8L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5VcGRhdGluZyBh

bmQgdmFsaWRhdGluZyB0aGUgQ2hhcmxzb24gY29tb3JiaWRpdHkgaW5kZXggYW5kIHNjb3JlIGZv

ciByaXNrIGFkanVzdG1lbnQgaW4gaG9zcGl0YWwgZGlzY2hhcmdlIGFic3RyYWN0cyB1c2luZyBk

YXRhIGZyb20gNiBjb3VudHJpZXM8L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+QW0gSiBFcGlkZW1p

b2w8L3NlY29uZGFyeS10aXRsZT48YWx0LXRpdGxlPkFtZXJpY2FuIGpvdXJuYWwgb2YgZXBpZGVt

aW9sb2d5PC9hbHQtdGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+QW0gSiBF

cGlkZW1pb2w8L2Z1bGwtdGl0bGU+PGFiYnItMT5BbWVyaWNhbiBqb3VybmFsIG9mIGVwaWRlbWlv

bG9neTwvYWJici0xPjwvcGVyaW9kaWNhbD48YWx0LXBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+QW0g

SiBFcGlkZW1pb2w8L2Z1bGwtdGl0bGU+PGFiYnItMT5BbWVyaWNhbiBqb3VybmFsIG9mIGVwaWRl

bWlvbG9neTwvYWJici0xPjwvYWx0LXBlcmlvZGljYWw+PHBhZ2VzPjY3Ni04MjwvcGFnZXM+PHZv

bHVtZT4xNzM8L3ZvbHVtZT48bnVtYmVyPjY8L251bWJlcj48ZWRpdGlvbj4yMDExLzAyLzE5PC9l

ZGl0aW9uPjxrZXl3b3Jkcz48a2V5d29yZD5BZHVsdDwva2V5d29yZD48a2V5d29yZD5BZ2UgRmFj

dG9yczwva2V5d29yZD48a2V5d29yZD5BZ2VkPC9rZXl3b3JkPjxrZXl3b3JkPkF1c3RyYWxpYS9l

cGlkZW1pb2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+Q2FuYWRhL2VwaWRlbWlvbG9neTwva2V5d29y

ZD48a2V5d29yZD4qQ29tb3JiaWRpdHk8L2tleXdvcmQ+PGtleXdvcmQ+Q29zdCBvZiBJbGxuZXNz

PC9rZXl3b3JkPjxrZXl3b3JkPkRpYWdub3Npcy1SZWxhdGVkIEdyb3Vwcy9zdGF0aXN0aWNzICZh

bXA7IG51bWVyaWNhbCBkYXRhPC9rZXl3b3JkPjxrZXl3b3JkPkZlbWFsZTwva2V5d29yZD48a2V5

d29yZD5GcmFuY2UvZXBpZGVtaW9sb2d5PC9rZXl3b3JkPjxrZXl3b3JkPipIb3NwaXRhbCBNb3J0

YWxpdHk8L2tleXdvcmQ+PGtleXdvcmQ+SHVtYW5zPC9rZXl3b3JkPjxrZXl3b3JkPkphcGFuL2Vw

aWRlbWlvbG9neTwva2V5d29yZD48a2V5d29yZD5NYWxlPC9rZXl3b3JkPjxrZXl3b3JkPk1pZGRs

ZSBBZ2VkPC9rZXl3b3JkPjxrZXl3b3JkPk1vcnRhbGl0eTwva2V5d29yZD48a2V5d29yZD5OZXcg

WmVhbGFuZC9lcGlkZW1pb2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+UGF0aWVudCBEaXNjaGFyZ2Uv

KnN0YXRpc3RpY3MgJmFtcDsgbnVtZXJpY2FsIGRhdGE8L2tleXdvcmQ+PGtleXdvcmQ+UHJvcG9y

dGlvbmFsIEhhemFyZHMgTW9kZWxzPC9rZXl3b3JkPjxrZXl3b3JkPlJpc2sgQWRqdXN0bWVudDwv

a2V5d29yZD48a2V5d29yZD5TZXggRmFjdG9yczwva2V5d29yZD48a2V5d29yZD5Td2l0emVybGFu

ZC9lcGlkZW1pb2xvZ3k8L2tleXdvcmQ+PC9rZXl3b3Jkcz48ZGF0ZXM+PHllYXI+MjAxMTwveWVh

cj48cHViLWRhdGVzPjxkYXRlPk1hciAxNTwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2Ju

PjAwMDItOTI2MjwvaXNibj48YWNjZXNzaW9uLW51bT4yMTMzMDMzOTwvYWNjZXNzaW9uLW51bT48

dXJscz48L3VybHM+PGVsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjEwLjEwOTMvYWplL2t3cTQzMzwv

ZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+PHJlbW90ZS1kYXRhYmFzZS1wcm92aWRlcj5OTE08L3Jl

bW90ZS1kYXRhYmFzZS1wcm92aWRlcj48bGFuZ3VhZ2U+ZW5nPC9sYW5ndWFnZT48L3JlY29yZD48

L0NpdGU+PENpdGU+PEF1dGhvcj5DaGFybHNvbjwvQXV0aG9yPjxZZWFyPjE5ODc8L1llYXI+PFJl

Y051bT40NjwvUmVjTnVtPjxyZWNvcmQ+PHJlYy1udW1iZXI+NDY8L3JlYy1udW1iZXI+PGZvcmVp

Z24ta2V5cz48a2V5IGFwcD0iRU4iIGRiLWlkPSI1cGR3cnY5OTN4ZHJ4aGVwdDV4dmVlZDRyeGV3

eGF3dDB2eHgiIHRpbWVzdGFtcD0iMTU0MjcwMDAxMyI+NDY8L2tleT48L2ZvcmVpZ24ta2V5cz48

cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9y

cz48YXV0aG9ycz48YXV0aG9yPkNoYXJsc29uLCBNLiBFLjwvYXV0aG9yPjxhdXRob3I+UG9tcGVp

LCBQLjwvYXV0aG9yPjxhdXRob3I+QWxlcywgSy4gTC48L2F1dGhvcj48YXV0aG9yPk1hY0tlbnpp

ZSwgQy4gUi48L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PHRpdGxlcz48dGl0bGU+

QSBuZXcgbWV0aG9kIG9mIGNsYXNzaWZ5aW5nIHByb2dub3N0aWMgY29tb3JiaWRpdHkgaW4gbG9u

Z2l0dWRpbmFsIHN0dWRpZXM6IGRldmVsb3BtZW50IGFuZCB2YWxpZGF0aW9uPC90aXRsZT48c2Vj

b25kYXJ5LXRpdGxlPkogQ2hyb25pYyBEaXM8L3NlY29uZGFyeS10aXRsZT48YWx0LXRpdGxlPkpv

dXJuYWwgb2YgY2hyb25pYyBkaXNlYXNlczwvYWx0LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2RpY2Fs

PjxmdWxsLXRpdGxlPkogQ2hyb25pYyBEaXM8L2Z1bGwtdGl0bGU+PGFiYnItMT5Kb3VybmFsIG9m

IGNocm9uaWMgZGlzZWFzZXM8L2FiYnItMT48L3BlcmlvZGljYWw+PGFsdC1wZXJpb2RpY2FsPjxm

dWxsLXRpdGxlPkogQ2hyb25pYyBEaXM8L2Z1bGwtdGl0bGU+PGFiYnItMT5Kb3VybmFsIG9mIGNo

cm9uaWMgZGlzZWFzZXM8L2FiYnItMT48L2FsdC1wZXJpb2RpY2FsPjxwYWdlcz4zNzMtODM8L3Bh

Z2VzPjx2b2x1bWU+NDA8L3ZvbHVtZT48bnVtYmVyPjU8L251bWJlcj48ZWRpdGlvbj4xOTg3LzAx

LzAxPC9lZGl0aW9uPjxrZXl3b3Jkcz48a2V5d29yZD5BY3R1YXJpYWwgQW5hbHlzaXM8L2tleXdv

cmQ+PGtleXdvcmQ+QWdlIEZhY3RvcnM8L2tleXdvcmQ+PGtleXdvcmQ+QnJlYXN0IE5lb3BsYXNt

cy9lcGlkZW1pb2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+KkVwaWRlbWlvbG9naWMgTWV0aG9kczwv

a2V5d29yZD48a2V5d29yZD5GZW1hbGU8L2tleXdvcmQ+PGtleXdvcmQ+Rm9sbG93LVVwIFN0dWRp

ZXM8L2tleXdvcmQ+PGtleXdvcmQ+SHVtYW5zPC9rZXl3b3JkPjxrZXl3b3JkPipMb25naXR1ZGlu

YWwgU3R1ZGllczwva2V5d29yZD48a2V5d29yZD4qTW9yYmlkaXR5PC9rZXl3b3JkPjxrZXl3b3Jk

Pk5ldyBZb3JrIENpdHk8L2tleXdvcmQ+PGtleXdvcmQ+UHJvZ25vc2lzPC9rZXl3b3JkPjxrZXl3

b3JkPlByb3NwZWN0aXZlIFN0dWRpZXM8L2tleXdvcmQ+PGtleXdvcmQ+Umlzazwva2V5d29yZD48

L2tleXdvcmRzPjxkYXRlcz48eWVhcj4xOTg3PC95ZWFyPjwvZGF0ZXM+PGlzYm4+MDAyMS05Njgx

IChQcmludCkmI3hEOzAwMjEtOTY4MTwvaXNibj48YWNjZXNzaW9uLW51bT4zNTU4NzE2PC9hY2Nl

c3Npb24tbnVtPjx1cmxzPjwvdXJscz48cmVtb3RlLWRhdGFiYXNlLXByb3ZpZGVyPk5MTTwvcmVt

b3RlLWRhdGFiYXNlLXByb3ZpZGVyPjxsYW5ndWFnZT5lbmc8L2xhbmd1YWdlPjwvcmVjb3JkPjwv

Q2l0ZT48Q2l0ZT48QXV0aG9yPktoYW48L0F1dGhvcj48WWVhcj4yMDEwPC9ZZWFyPjxSZWNOdW0+

NDc8L1JlY051bT48cmVjb3JkPjxyZWMtbnVtYmVyPjQ3PC9yZWMtbnVtYmVyPjxmb3JlaWduLWtl

eXM+PGtleSBhcHA9IkVOIiBkYi1pZD0iNXBkd3J2OTkzeGRyeGhlcHQ1eHZlZWQ0cnhld3hhd3Qw

dnh4IiB0aW1lc3RhbXA9IjE1NDI3MDAxMTEiPjQ3PC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10

eXBlIG5hbWU9IkpvdXJuYWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1

dGhvcnM+PGF1dGhvcj5LaGFuLCBOLiBGLjwvYXV0aG9yPjxhdXRob3I+UGVyZXJhLCBSLjwvYXV0

aG9yPjxhdXRob3I+SGFycGVyLCBTLjwvYXV0aG9yPjxhdXRob3I+Um9zZSwgUC4gVy48L2F1dGhv

cj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5EZXBhcnRtZW50IG9mIFBy

aW1hcnkgSGVhbHRoIENhcmUsIFVuaXZlcnNpdHkgb2YgT3hmb3JkLCBPbGQgUm9hZCBDYW1wdXMs

IE94Zm9yZCBPWDMgN0xGLCBVSy4gbmFkYS5raGFuQGRwaHBjLm94LmFjLnVrPC9hdXRoLWFkZHJl

c3M+PHRpdGxlcz48dGl0bGU+QWRhcHRhdGlvbiBhbmQgdmFsaWRhdGlvbiBvZiB0aGUgQ2hhcmxz

b24gSW5kZXggZm9yIFJlYWQvT1hNSVMgY29kZWQgZGF0YWJhc2VzPC90aXRsZT48c2Vjb25kYXJ5

LXRpdGxlPkJNQyBGYW0gUHJhY3Q8L3NlY29uZGFyeS10aXRsZT48YWx0LXRpdGxlPkJNQyBmYW1p

bHkgcHJhY3RpY2U8L2FsdC10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5C

TUMgRmFtIFByYWN0PC9mdWxsLXRpdGxlPjxhYmJyLTE+Qk1DIGZhbWlseSBwcmFjdGljZTwvYWJi

ci0xPjwvcGVyaW9kaWNhbD48YWx0LXBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+Qk1DIEZhbSBQcmFj

dDwvZnVsbC10aXRsZT48YWJici0xPkJNQyBmYW1pbHkgcHJhY3RpY2U8L2FiYnItMT48L2FsdC1w

ZXJpb2RpY2FsPjxwYWdlcz4xPC9wYWdlcz48dm9sdW1lPjExPC92b2x1bWU+PGVkaXRpb24+MjAx

MC8wMS8wNzwvZWRpdGlvbj48a2V5d29yZHM+PGtleXdvcmQ+Q2xpbmljYWwgTWVkaWNpbmUvY2xh

c3NpZmljYXRpb248L2tleXdvcmQ+PGtleXdvcmQ+KkNvbW9yYmlkaXR5PC9rZXl3b3JkPjxrZXl3

b3JkPkRhdGFiYXNlcywgRmFjdHVhbDwva2V5d29yZD48a2V5d29yZD4qRmFtaWx5IFByYWN0aWNl

PC9rZXl3b3JkPjxrZXl3b3JkPkhpc3RvcnksIDIwdGggQ2VudHVyeTwva2V5d29yZD48a2V5d29y

ZD5IdW1hbnM8L2tleXdvcmQ+PGtleXdvcmQ+TG9naXN0aWMgTW9kZWxzPC9rZXl3b3JkPjxrZXl3

b3JkPipNb3J0YWxpdHk8L2tleXdvcmQ+PGtleXdvcmQ+UHJpbWFyeSBIZWFsdGggQ2FyZS9jbGFz

c2lmaWNhdGlvbjwva2V5d29yZD48a2V5d29yZD5Qcm9wb3J0aW9uYWwgSGF6YXJkcyBNb2RlbHM8

L2tleXdvcmQ+PGtleXdvcmQ+U29mdHdhcmU8L2tleXdvcmQ+PGtleXdvcmQ+KlZvY2FidWxhcnks

IENvbnRyb2xsZWQvaGlzdG9yeTwva2V5d29yZD48L2tleXdvcmRzPjxkYXRlcz48eWVhcj4yMDEw

PC95ZWFyPjxwdWItZGF0ZXM+PGRhdGU+SmFuIDU8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48

aXNibj4xNDcxLTIyOTY8L2lzYm4+PGFjY2Vzc2lvbi1udW0+MjAwNTExMTA8L2FjY2Vzc2lvbi1u

dW0+PHVybHM+PC91cmxzPjxjdXN0b20yPlBNQzI4MjA0Njg8L2N1c3RvbTI+PGVsZWN0cm9uaWMt

cmVzb3VyY2UtbnVtPjEwLjExODYvMTQ3MS0yMjk2LTExLTE8L2VsZWN0cm9uaWMtcmVzb3VyY2Ut

bnVtPjxyZW1vdGUtZGF0YWJhc2UtcHJvdmlkZXI+TkxNPC9yZW1vdGUtZGF0YWJhc2UtcHJvdmlk

ZXI+PGxhbmd1YWdlPmVuZzwvbGFuZ3VhZ2U+PC9yZWNvcmQ+PC9DaXRlPjwvRW5kTm90ZT4A

ADDIN EN.CITE.DATA [1, 2, 3, 4]. The Quan-adapted CCI score in IHD was calculated with ICD-10 and enhanced ICD-9 codes from Quan et al. (2005) ADDIN EN.CITE <EndNote><Cite><Author>Quan</Author><Year>2005</Year><RecNum>43</RecNum><DisplayText>[1]</DisplayText><record><rec-number>43</rec-number><foreign-keys><key app="EN" db-id="5pdwrv993xdrxhept5xveed4rxewxawt0vxx" timestamp="1540824807">43</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Quan, H.</author><author>Sundararajan, V.</author><author>Halfon, P.</author><author>Fong, A.</author><author>Burnand, B.</author><author>Luthi, J. C.</author><author>Saunders, L. D.</author><author>Beck, C. A.</author><author>Feasby, T. E.</author><author>Ghali, W. A.</author></authors></contributors><auth-address>Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada. hquan@ucalgary.ca</auth-address><titles><title>Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data</title><secondary-title>Med Care</secondary-title><alt-title>Medical care</alt-title></titles><periodical><full-title>Med Care</full-title><abbr-1>Medical care</abbr-1></periodical><alt-periodical><full-title>Med Care</full-title><abbr-1>Medical care</abbr-1></alt-periodical><pages>1130-9</pages><volume>43</volume><number>11</number><edition>2005/10/15</edition><keywords><keyword>*Algorithms</keyword><keyword>Canada/epidemiology</keyword><keyword>*Comorbidity</keyword><keyword>Disease/classification</keyword><keyword>Female</keyword><keyword>Forms and Records Control/*methods</keyword><keyword>Hospital Mortality</keyword><keyword>Humans</keyword><keyword>*International Classification of Diseases</keyword><keyword>Male</keyword><keyword>Medical Records/classification</keyword><keyword>Middle Aged</keyword><keyword>Models, Statistical</keyword><keyword>Risk Adjustment</keyword></keywords><dates><year>2005</year><pub-dates><date>Nov</date></pub-dates></dates><isbn>0025-7079 (Print)&#xD;0025-7079</isbn><accession-num>16224307</accession-num><urls></urls><remote-database-provider>NLM</remote-database-provider><language>eng</language></record></Cite></EndNote>[1] along with updated weights from Quan et al. (2011) PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5RdWFuPC9BdXRob3I+PFllYXI+MjAxMTwvWWVhcj48UmVj

TnVtPjQ0PC9SZWNOdW0+PERpc3BsYXlUZXh0PlsyXTwvRGlzcGxheVRleHQ+PHJlY29yZD48cmVj

LW51bWJlcj40NDwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9

IjVwZHdydjk5M3hkcnhoZXB0NXh2ZWVkNHJ4ZXd4YXd0MHZ4eCIgdGltZXN0YW1wPSIxNTQwODI0

ODcwIj40NDwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFydGlj

bGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+UXVhbiwgSC48

L2F1dGhvcj48YXV0aG9yPkxpLCBCLjwvYXV0aG9yPjxhdXRob3I+Q291cmlzLCBDLiBNLjwvYXV0

aG9yPjxhdXRob3I+RnVzaGltaSwgSy48L2F1dGhvcj48YXV0aG9yPkdyYWhhbSwgUC48L2F1dGhv

cj48YXV0aG9yPkhpZGVyLCBQLjwvYXV0aG9yPjxhdXRob3I+SmFudWVsLCBKLiBNLjwvYXV0aG9y

PjxhdXRob3I+U3VuZGFyYXJhamFuLCBWLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9y

cz48YXV0aC1hZGRyZXNzPkRlcGFydG1lbnQgb2YgQ29tbXVuaXR5IEhlYWx0aCBTY2llbmNlcywg

RmFjdWx0eSBvZiBNZWRpY2luZSwgVW5pdmVyc2l0eSBvZiBDYWxnYXJ5LCAzMjgwIEhvc3BpdGFs

IERyaXZlIE5XLCBDYWxnYXJ5LCBBbGJlcnRhLCBDYW5hZGEgVDJOIDRaNi4gaHF1YW5AdWNhbGdh

cnkuY2E8L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5VcGRhdGluZyBhbmQgdmFsaWRhdGlu

ZyB0aGUgQ2hhcmxzb24gY29tb3JiaWRpdHkgaW5kZXggYW5kIHNjb3JlIGZvciByaXNrIGFkanVz

dG1lbnQgaW4gaG9zcGl0YWwgZGlzY2hhcmdlIGFic3RyYWN0cyB1c2luZyBkYXRhIGZyb20gNiBj

b3VudHJpZXM8L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+QW0gSiBFcGlkZW1pb2w8L3NlY29uZGFy

eS10aXRsZT48YWx0LXRpdGxlPkFtZXJpY2FuIGpvdXJuYWwgb2YgZXBpZGVtaW9sb2d5PC9hbHQt

dGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+QW0gSiBFcGlkZW1pb2w8L2Z1

bGwtdGl0bGU+PGFiYnItMT5BbWVyaWNhbiBqb3VybmFsIG9mIGVwaWRlbWlvbG9neTwvYWJici0x

PjwvcGVyaW9kaWNhbD48YWx0LXBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+QW0gSiBFcGlkZW1pb2w8

L2Z1bGwtdGl0bGU+PGFiYnItMT5BbWVyaWNhbiBqb3VybmFsIG9mIGVwaWRlbWlvbG9neTwvYWJi

ci0xPjwvYWx0LXBlcmlvZGljYWw+PHBhZ2VzPjY3Ni04MjwvcGFnZXM+PHZvbHVtZT4xNzM8L3Zv

bHVtZT48bnVtYmVyPjY8L251bWJlcj48ZWRpdGlvbj4yMDExLzAyLzE5PC9lZGl0aW9uPjxrZXl3

b3Jkcz48a2V5d29yZD5BZHVsdDwva2V5d29yZD48a2V5d29yZD5BZ2UgRmFjdG9yczwva2V5d29y

ZD48a2V5d29yZD5BZ2VkPC9rZXl3b3JkPjxrZXl3b3JkPkF1c3RyYWxpYS9lcGlkZW1pb2xvZ3k8

L2tleXdvcmQ+PGtleXdvcmQ+Q2FuYWRhL2VwaWRlbWlvbG9neTwva2V5d29yZD48a2V5d29yZD4q

Q29tb3JiaWRpdHk8L2tleXdvcmQ+PGtleXdvcmQ+Q29zdCBvZiBJbGxuZXNzPC9rZXl3b3JkPjxr

ZXl3b3JkPkRpYWdub3Npcy1SZWxhdGVkIEdyb3Vwcy9zdGF0aXN0aWNzICZhbXA7IG51bWVyaWNh

bCBkYXRhPC9rZXl3b3JkPjxrZXl3b3JkPkZlbWFsZTwva2V5d29yZD48a2V5d29yZD5GcmFuY2Uv

ZXBpZGVtaW9sb2d5PC9rZXl3b3JkPjxrZXl3b3JkPipIb3NwaXRhbCBNb3J0YWxpdHk8L2tleXdv

cmQ+PGtleXdvcmQ+SHVtYW5zPC9rZXl3b3JkPjxrZXl3b3JkPkphcGFuL2VwaWRlbWlvbG9neTwv

a2V5d29yZD48a2V5d29yZD5NYWxlPC9rZXl3b3JkPjxrZXl3b3JkPk1pZGRsZSBBZ2VkPC9rZXl3

b3JkPjxrZXl3b3JkPk1vcnRhbGl0eTwva2V5d29yZD48a2V5d29yZD5OZXcgWmVhbGFuZC9lcGlk

ZW1pb2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+UGF0aWVudCBEaXNjaGFyZ2UvKnN0YXRpc3RpY3Mg

JmFtcDsgbnVtZXJpY2FsIGRhdGE8L2tleXdvcmQ+PGtleXdvcmQ+UHJvcG9ydGlvbmFsIEhhemFy

ZHMgTW9kZWxzPC9rZXl3b3JkPjxrZXl3b3JkPlJpc2sgQWRqdXN0bWVudDwva2V5d29yZD48a2V5

d29yZD5TZXggRmFjdG9yczwva2V5d29yZD48a2V5d29yZD5Td2l0emVybGFuZC9lcGlkZW1pb2xv

Z3k8L2tleXdvcmQ+PC9rZXl3b3Jkcz48ZGF0ZXM+PHllYXI+MjAxMTwveWVhcj48cHViLWRhdGVz

PjxkYXRlPk1hciAxNTwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2JuPjAwMDItOTI2Mjwv

aXNibj48YWNjZXNzaW9uLW51bT4yMTMzMDMzOTwvYWNjZXNzaW9uLW51bT48dXJscz48L3VybHM+

PGVsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjEwLjEwOTMvYWplL2t3cTQzMzwvZWxlY3Ryb25pYy1y

ZXNvdXJjZS1udW0+PHJlbW90ZS1kYXRhYmFzZS1wcm92aWRlcj5OTE08L3JlbW90ZS1kYXRhYmFz

ZS1wcm92aWRlcj48bGFuZ3VhZ2U+ZW5nPC9sYW5ndWFnZT48L3JlY29yZD48L0NpdGU+PC9FbmRO

b3RlPn==

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5RdWFuPC9BdXRob3I+PFllYXI+MjAxMTwvWWVhcj48UmVj

TnVtPjQ0PC9SZWNOdW0+PERpc3BsYXlUZXh0PlsyXTwvRGlzcGxheVRleHQ+PHJlY29yZD48cmVj

LW51bWJlcj40NDwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9

IjVwZHdydjk5M3hkcnhoZXB0NXh2ZWVkNHJ4ZXd4YXd0MHZ4eCIgdGltZXN0YW1wPSIxNTQwODI0

ODcwIj40NDwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFydGlj

bGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+UXVhbiwgSC48

L2F1dGhvcj48YXV0aG9yPkxpLCBCLjwvYXV0aG9yPjxhdXRob3I+Q291cmlzLCBDLiBNLjwvYXV0

aG9yPjxhdXRob3I+RnVzaGltaSwgSy48L2F1dGhvcj48YXV0aG9yPkdyYWhhbSwgUC48L2F1dGhv

cj48YXV0aG9yPkhpZGVyLCBQLjwvYXV0aG9yPjxhdXRob3I+SmFudWVsLCBKLiBNLjwvYXV0aG9y

PjxhdXRob3I+U3VuZGFyYXJhamFuLCBWLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9y

cz48YXV0aC1hZGRyZXNzPkRlcGFydG1lbnQgb2YgQ29tbXVuaXR5IEhlYWx0aCBTY2llbmNlcywg

RmFjdWx0eSBvZiBNZWRpY2luZSwgVW5pdmVyc2l0eSBvZiBDYWxnYXJ5LCAzMjgwIEhvc3BpdGFs

IERyaXZlIE5XLCBDYWxnYXJ5LCBBbGJlcnRhLCBDYW5hZGEgVDJOIDRaNi4gaHF1YW5AdWNhbGdh

cnkuY2E8L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5VcGRhdGluZyBhbmQgdmFsaWRhdGlu

ZyB0aGUgQ2hhcmxzb24gY29tb3JiaWRpdHkgaW5kZXggYW5kIHNjb3JlIGZvciByaXNrIGFkanVz

dG1lbnQgaW4gaG9zcGl0YWwgZGlzY2hhcmdlIGFic3RyYWN0cyB1c2luZyBkYXRhIGZyb20gNiBj

b3VudHJpZXM8L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+QW0gSiBFcGlkZW1pb2w8L3NlY29uZGFy

eS10aXRsZT48YWx0LXRpdGxlPkFtZXJpY2FuIGpvdXJuYWwgb2YgZXBpZGVtaW9sb2d5PC9hbHQt

dGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+QW0gSiBFcGlkZW1pb2w8L2Z1

bGwtdGl0bGU+PGFiYnItMT5BbWVyaWNhbiBqb3VybmFsIG9mIGVwaWRlbWlvbG9neTwvYWJici0x

PjwvcGVyaW9kaWNhbD48YWx0LXBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+QW0gSiBFcGlkZW1pb2w8

L2Z1bGwtdGl0bGU+PGFiYnItMT5BbWVyaWNhbiBqb3VybmFsIG9mIGVwaWRlbWlvbG9neTwvYWJi

ci0xPjwvYWx0LXBlcmlvZGljYWw+PHBhZ2VzPjY3Ni04MjwvcGFnZXM+PHZvbHVtZT4xNzM8L3Zv

bHVtZT48bnVtYmVyPjY8L251bWJlcj48ZWRpdGlvbj4yMDExLzAyLzE5PC9lZGl0aW9uPjxrZXl3

b3Jkcz48a2V5d29yZD5BZHVsdDwva2V5d29yZD48a2V5d29yZD5BZ2UgRmFjdG9yczwva2V5d29y

ZD48a2V5d29yZD5BZ2VkPC9rZXl3b3JkPjxrZXl3b3JkPkF1c3RyYWxpYS9lcGlkZW1pb2xvZ3k8

L2tleXdvcmQ+PGtleXdvcmQ+Q2FuYWRhL2VwaWRlbWlvbG9neTwva2V5d29yZD48a2V5d29yZD4q

Q29tb3JiaWRpdHk8L2tleXdvcmQ+PGtleXdvcmQ+Q29zdCBvZiBJbGxuZXNzPC9rZXl3b3JkPjxr

ZXl3b3JkPkRpYWdub3Npcy1SZWxhdGVkIEdyb3Vwcy9zdGF0aXN0aWNzICZhbXA7IG51bWVyaWNh

bCBkYXRhPC9rZXl3b3JkPjxrZXl3b3JkPkZlbWFsZTwva2V5d29yZD48a2V5d29yZD5GcmFuY2Uv

ZXBpZGVtaW9sb2d5PC9rZXl3b3JkPjxrZXl3b3JkPipIb3NwaXRhbCBNb3J0YWxpdHk8L2tleXdv

cmQ+PGtleXdvcmQ+SHVtYW5zPC9rZXl3b3JkPjxrZXl3b3JkPkphcGFuL2VwaWRlbWlvbG9neTwv

a2V5d29yZD48a2V5d29yZD5NYWxlPC9rZXl3b3JkPjxrZXl3b3JkPk1pZGRsZSBBZ2VkPC9rZXl3

b3JkPjxrZXl3b3JkPk1vcnRhbGl0eTwva2V5d29yZD48a2V5d29yZD5OZXcgWmVhbGFuZC9lcGlk

ZW1pb2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+UGF0aWVudCBEaXNjaGFyZ2UvKnN0YXRpc3RpY3Mg

JmFtcDsgbnVtZXJpY2FsIGRhdGE8L2tleXdvcmQ+PGtleXdvcmQ+UHJvcG9ydGlvbmFsIEhhemFy

ZHMgTW9kZWxzPC9rZXl3b3JkPjxrZXl3b3JkPlJpc2sgQWRqdXN0bWVudDwva2V5d29yZD48a2V5

d29yZD5TZXggRmFjdG9yczwva2V5d29yZD48a2V5d29yZD5Td2l0emVybGFuZC9lcGlkZW1pb2xv

Z3k8L2tleXdvcmQ+PC9rZXl3b3Jkcz48ZGF0ZXM+PHllYXI+MjAxMTwveWVhcj48cHViLWRhdGVz

PjxkYXRlPk1hciAxNTwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2JuPjAwMDItOTI2Mjwv

aXNibj48YWNjZXNzaW9uLW51bT4yMTMzMDMzOTwvYWNjZXNzaW9uLW51bT48dXJscz48L3VybHM+

PGVsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjEwLjEwOTMvYWplL2t3cTQzMzwvZWxlY3Ryb25pYy1y

ZXNvdXJjZS1udW0+PHJlbW90ZS1kYXRhYmFzZS1wcm92aWRlcj5OTE08L3JlbW90ZS1kYXRhYmFz

ZS1wcm92aWRlcj48bGFuZ3VhZ2U+ZW5nPC9sYW5ndWFnZT48L3JlY29yZD48L0NpdGU+PC9FbmRO

b3RlPn==

ADDIN EN.CITE.DATA [2]. The weights were assigned to disease states based on the following rules:1 point for each of the following: chronic pulmonary disease, rheumatologic disease, diabetes with chronic complications, renal disease2 points for each of the following: congestive heart failure, dementia, mild liver disease, hemiplegia or paraplegia, any malignancy4 points for each of the following: moderate or severe liver disease, acquired immune deficiency syndrome (AIDS)/human immunodeficiency virus (HIV)6 points for each of the following: metastatic solid tumorNote that liver disease and cancer were only given points for the higher weighted disease state (eg, for patients with both “mild liver disease" and “moderate or severe liver disease", points were only given for “moderate or severe liver disease"). Figure A: Flowchart of population inclusion/exclusion criteria to identify DLBCL patients ≥ 66 years at diagnosis with continuous enrollment in Medicare at least one year prior to diagnosis.-13017523495000Figure B: Study diagram illustrating treatment lines received.The visual shows an example of the patient viewer in IHD, which allows the display of treatments over time, as well as the results of the variable “Any TX from 1st line 56d segments BHE” used to classify lines. Example patient #1 received Doxorubicin, Rituximab and Vincristine on the same day, followed by the same regimen one more time, then only received treatment with Rituximab. This patient was classified, based on our rules, as receiving Doxorubicin, Rituximab and Vincristine as Line 1, with no subsequent line of treatment.Another patient profile (Patient #2) has a different treatment pattern. Patient #2 had 3 lines of therapy based on our rules. Line 1 = Cyclophosphamide + Doxorubicin + Rituximab + Vincristine; Line 2 = Methotrexate; Line 3 = Hematopoietic stem cell transplant + Methotrexate.Table A: Conditions and Codes for Calculating CCI.IHD Provided: Quan ICD10 Charlson AIDS 2018-08 [ICD-10 Diagnosis]CodeDescriptionB20Human immunodeficiency virus [HIV] diseaseIHD Provided: Quan ICD10 Charlson Chronic Pulmonary Disease 2018-08 [ICD-10 Diagnosis]CodeDescriptionI27.81Cor pulmonale (chronic)I27.82Chronic pulmonary embolismI27.83Eisenmenger's syndromeI27.89Other specified pulmonary heart diseasesI27.9Pulmonary heart disease, unspecifiedJ40Bronchitis, not specified as acute or chronicJ41.0Simple chronic bronchitisJ41.1Mucopurulent chronic bronchitisJ41.8Mixed simple and mucopurulent chronic bronchitisJ42Unspecified chronic bronchitisJ43.0Unilateral pulmonary emphysema [MacLeod's syndrome]J43.1Panlobular emphysemaJ43.2Centrilobular emphysemaJ43.8Other emphysemaJ43.9Emphysema, unspecifiedJ44.0Chronic obstructive pulmonary disease with acute lower respiratory infectionJ44.1Chronic obstructive pulmonary disease with (acute) exacerbationJ44.9Chronic obstructive pulmonary disease, unspecifiedJ45.20Mild intermittent asthma, uncomplicatedJ45.21Mild intermittent asthma with (acute) exacerbationJ45.22Mild intermittent asthma with status asthmaticusJ45.30Mild persistent asthma, uncomplicatedJ45.31Mild persistent asthma with (acute) exacerbationJ45.32Mild persistent asthma with status asthmaticusJ45.40Moderate persistent asthma, uncomplicatedJ45.41Moderate persistent asthma with (acute) exacerbationJ45.42Moderate persistent asthma with status asthmaticusJ45.50Severe persistent asthma, uncomplicatedJ45.51Severe persistent asthma with (acute) exacerbationJ45.52Severe persistent asthma with status asthmaticusJ45.901Unspecified asthma with (acute) exacerbationJ45.902Unspecified asthma with status asthmaticusJ45.909Unspecified asthma, uncomplicatedJ45.990Exercise induced bronchospasmJ45.991Cough variant asthmaJ45.998Other asthmaJ47.0Bronchiectasis with acute lower respiratory infectionJ47.1Bronchiectasis with (acute) exacerbationJ47.9Bronchiectasis, uncomplicatedJ60Coalworker's pneumoconiosisJ61Pneumoconiosis due to asbestos and other mineral fibersJ62.0Pneumoconiosis due to talc dustJ62.8Pneumoconiosis due to other dust containing silicaJ63.0Aluminosis (of lung)J63.1Bauxite fibrosis (of lung)J63.2BerylliosisJ63.3Graphite fibrosis (of lung)J63.4SiderosisJ63.5StannosisJ63.6Pneumoconiosis due to other specified inorganic dustsJ64Unspecified pneumoconiosisJ65Pneumoconiosis associated with tuberculosisJ66.0ByssinosisJ66.1Flax-dressers' diseaseJ66.2CannabinosisJ66.8Airway disease due to other specific organic dustsJ67.0Farmer's lungJ67.1BagassosisJ67.2Bird fancier's lungJ67.3SuberosisJ67.4Maltworker's lungJ67.5Mushroom-worker's lungJ67.6Maple-bark-stripper's lungJ67.7Air conditioner and humidifier lungJ67.8Hypersensitivity pneumonitis due to other organic dustsJ67.9Hypersensitivity pneumonitis due to unspecified organic dustJ68.4Chronic respiratory conditions due to chemicals, gases, fumes and vaporsJ70.1Chronic and other pulmonary manifestations due to radiationJ70.3Chronic drug-induced interstitial lung disordersIHD Provided: Quan ICD10 Charlson Congestive Heart Failure 2018-08 [ICD-10 Diagnosis]CodeDescriptionI09.9Rheumatic heart disease, unspecifiedI11.0Hypertensive heart disease with heart failureI13.0Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney diseaseI13.2Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal diseaseI25.5Ischemic cardiomyopathyI42.0Dilated cardiomyopathyI42.5Other restrictive cardiomyopathyI42.6Alcoholic cardiomyopathyI42.7Cardiomyopathy due to drug and external agentI42.8Other cardiomyopathiesI42.9Cardiomyopathy, unspecifiedI43Cardiomyopathy in diseases classified elsewhereI50.1Left ventricular failure, unspecifiedI50.20Unspecified systolic (congestive) heart failureI50.21Acute systolic (congestive) heart failureI50.22Chronic systolic (congestive) heart failureI50.23Acute on chronic systolic (congestive) heart failureI50.30Unspecified diastolic (congestive) heart failureI50.31Acute diastolic (congestive) heart failureI50.32Chronic diastolic (congestive) heart failureI50.33Acute on chronic diastolic (congestive) heart failureI50.40Unspecified combined systolic (congestive) and diastolic (congestive) heart failureI50.41Acute combined systolic (congestive) and diastolic (congestive) heart failureI50.42Chronic combined systolic (congestive) and diastolic (congestive) heart failureI50.43Acute on chronic combined systolic (congestive) and diastolic (congestive) heart failureI50.810Right heart failure, unspecifiedI50.811Acute right heart failureI50.812Chronic right heart failureI50.813Acute on chronic right heart failureI50.814Right heart failure due to left heart failureI50.82Biventricular heart failureI50.83High output heart failureI50.84End stage heart failureI50.89Other heart failureI50.9Heart failure, unspecifiedP29.0Neonatal cardiac failureIHD Provided: Quan ICD10 Charlson Dementia 2018-08 [ICD-10 Diagnosis]CodeDescriptionF01.50Vascular dementia without behavioral disturbanceF01.51Vascular dementia with behavioral disturbanceF02.80Dementia in other diseases classified elsewhere without behavioral disturbanceF02.81Dementia in other diseases classified elsewhere with behavioral disturbanceF03.90Unspecified dementia without behavioral disturbanceF03.91Unspecified dementia with behavioral disturbanceG30.0Alzheimer's disease with early onsetG30.1Alzheimer's disease with late onsetG30.8Other Alzheimer's diseaseG30.9Alzheimer's disease, unspecifiedG31.1Senile degeneration of brain, not elsewhere classifiedIHD Provided: Quan ICD10 Charlson Hemiplegia or Paraplegia 2018-08 [ICD-10 Diagnosis]CodeDescriptionG04.1Tropical spastic paraplegiaG11.4Hereditary spastic paraplegiaG80.1Spastic diplegic cerebral palsyG80.2Spastic hemiplegic cerebral palsyG81.00Flaccid hemiplegia affecting unspecified sideG81.01Flaccid hemiplegia affecting right dominant sideG81.02Flaccid hemiplegia affecting left dominant sideG81.03Flaccid hemiplegia affecting right nondominant sideG81.04Flaccid hemiplegia affecting left nondominant sideG81.10Spastic hemiplegia affecting unspecified sideG81.11Spastic hemiplegia affecting right dominant sideG81.12Spastic hemiplegia affecting left dominant sideG81.13Spastic hemiplegia affecting right nondominant sideG81.14Spastic hemiplegia affecting left nondominant sideG81.90Hemiplegia, unspecified affecting unspecified sideG81.91Hemiplegia, unspecified affecting right dominant sideG81.92Hemiplegia, unspecified affecting left dominant sideG81.93Hemiplegia, unspecified affecting right nondominant sideG81.94Hemiplegia, unspecified affecting left nondominant sideG82.20Paraplegia, unspecifiedG82.21Paraplegia, completeG82.22Paraplegia, incompleteG82.50Quadriplegia, unspecifiedG82.51Quadriplegia, C1-C4 completeG82.52Quadriplegia, C1-C4 incompleteG82.53Quadriplegia, C5-C7 completeG82.54Quadriplegia, C5-C7 incompleteG83.0Diplegia of upper limbsG83.10Monoplegia of lower limb affecting unspecified sideG83.11Monoplegia of lower limb affecting right dominant sideG83.12Monoplegia of lower limb affecting left dominant sideG83.13Monoplegia of lower limb affecting right nondominant sideG83.14Monoplegia of lower limb affecting left nondominant sideG83.20Monoplegia of upper limb affecting unspecified sideG83.21Monoplegia of upper limb affecting right dominant sideG83.22Monoplegia of upper limb affecting left dominant sideG83.23Monoplegia of upper limb affecting right nondominant sideG83.24Monoplegia of upper limb affecting left nondominant sideG83.30Monoplegia, unspecified affecting unspecified sideG83.31Monoplegia, unspecified affecting right dominant sideG83.32Monoplegia, unspecified affecting left dominant sideG83.33Monoplegia, unspecified affecting right nondominant sideG83.34Monoplegia, unspecified affecting left nondominant sideG83.4Cauda equina syndromeG83.9Paralytic syndrome, unspecifiedIHD Provided: Quan ICD10 Charlson Metastatic Solid Tumor 2018-08 [ICD-10 Diagnosis]CodeDescriptionC77.0Secondary and unspecified malignant neoplasm of lymph nodes of head, face and neckC77.1Secondary and unspecified malignant neoplasm of intrathoracic lymph nodesC77.2Secondary and unspecified malignant neoplasm of intra-abdominal lymph nodesC77.3Secondary and unspecified malignant neoplasm of axilla and upper limb lymph nodesC77.4Secondary and unspecified malignant neoplasm of inguinal and lower limb lymph nodesC77.5Secondary and unspecified malignant neoplasm of intrapelvic lymph nodesC77.8Secondary and unspecified malignant neoplasm of lymph nodes of multiple regionsC77.9Secondary and unspecified malignant neoplasm of lymph node, unspecifiedC78.00Secondary malignant neoplasm of unspecified lungC78.01Secondary malignant neoplasm of right lungC78.02Secondary malignant neoplasm of left lungC78.1Secondary malignant neoplasm of mediastinumC78.2Secondary malignant neoplasm of pleuraC78.30Secondary malignant neoplasm of unspecified respiratory organC78.39Secondary malignant neoplasm of other respiratory organsC78.4Secondary malignant neoplasm of small intestineC78.5Secondary malignant neoplasm of large intestine and rectumC78.6Secondary malignant neoplasm of retroperitoneum and peritoneumC78.7Secondary malignant neoplasm of liver and intrahepatic bile ductC78.80Secondary malignant neoplasm of unspecified digestive organC78.89Secondary malignant neoplasm of other digestive organsC79.00Secondary malignant neoplasm of unspecified kidney and renal pelvisC79.01Secondary malignant neoplasm of right kidney and renal pelvisC79.02Secondary malignant neoplasm of left kidney and renal pelvisC79.10Secondary malignant neoplasm of unspecified urinary organsC79.11Secondary malignant neoplasm of bladderC79.19Secondary malignant neoplasm of other urinary organsC79.2Secondary malignant neoplasm of skinC79.31Secondary malignant neoplasm of brainC79.32Secondary malignant neoplasm of cerebral meningesC79.40Secondary malignant neoplasm of unspecified part of nervous systemC79.49Secondary malignant neoplasm of other parts of nervous systemC79.51Secondary malignant neoplasm of boneC79.52Secondary malignant neoplasm of bone marrowC79.60Secondary malignant neoplasm of unspecified ovaryC79.61Secondary malignant neoplasm of right ovaryC79.62Secondary malignant neoplasm of left ovaryC79.70Secondary malignant neoplasm of unspecified adrenal glandC79.71Secondary malignant neoplasm of right adrenal glandC79.72Secondary malignant neoplasm of left adrenal glandC79.81Secondary malignant neoplasm of breastC79.82Secondary malignant neoplasm of genital organsC79.89Secondary malignant neoplasm of other specified sitesC79.9Secondary malignant neoplasm of unspecified siteC80.0Disseminated malignant neoplasm, unspecifiedC80.1Malignant (primary) neoplasm, unspecifiedC80.2Malignant neoplasm associated with transplanted organIHD Provided: Quan ICD10 Charlson Mild Liver Disease 2018-08 [ICD-10 Diagnosis]CodeDescriptionB18.0Chronic viral hepatitis B with delta-agentB18.1Chronic viral hepatitis B without delta-agentB18.2Chronic viral hepatitis CB18.8Other chronic viral hepatitisB18.9Chronic viral hepatitis, unspecifiedK70.0Alcoholic fatty liverK70.10Alcoholic hepatitis without ascitesK70.11Alcoholic hepatitis with ascitesK70.2Alcoholic fibrosis and sclerosis of liverK70.30Alcoholic cirrhosis of liver without ascitesK70.31Alcoholic cirrhosis of liver with ascitesK70.9Alcoholic liver disease, unspecifiedK71.3Toxic liver disease with chronic persistent hepatitisK71.4Toxic liver disease with chronic lobular hepatitisK71.50Toxic liver disease with chronic active hepatitis without ascitesK71.51Toxic liver disease with chronic active hepatitis with ascitesK71.7Toxic liver disease with fibrosis and cirrhosis of liverK73.0Chronic persistent hepatitis, not elsewhere classifiedK73.1Chronic lobular hepatitis, not elsewhere classifiedK73.2Chronic active hepatitis, not elsewhere classifiedK73.8Other chronic hepatitis, not elsewhere classifiedK73.9Chronic hepatitis, unspecifiedK74.0Hepatic fibrosisK74.1Hepatic sclerosisK74.2Hepatic fibrosis with hepatic sclerosisK74.3Primary biliary cirrhosisK74.4Secondary biliary cirrhosisK74.5Biliary cirrhosis, unspecifiedK74.60Unspecified cirrhosis of liverK74.69Other cirrhosis of liverK76.0Fatty (change of) liver, not elsewhere classifiedK76.2Central hemorrhagic necrosis of liverK76.3Infarction of liverK76.4Peliosis hepatisK76.81Hepatopulmonary syndromeK76.89Other specified diseases of liverK76.9Liver disease, unspecifiedZ94.4Liver transplant statusIHD Provided: Quan ICD10 Charlson Mod Sev Liver Disease 2018-08 [ICD-10 Diagnosis]CodeDescriptionI85.00Esophageal varices without bleedingI85.01Esophageal varices with bleedingI86.4Gastric varicesK70.40Alcoholic hepatic failure without comaK70.41Alcoholic hepatic failure with comaK71.10Toxic liver disease with hepatic necrosis, without comaK71.11Toxic liver disease with hepatic necrosis, with comaK72.10Chronic hepatic failure without comaK72.11Chronic hepatic failure with comaK72.90Hepatic failure, unspecified without comaK72.91Hepatic failure, unspecified with comaK76.5Hepatic veno-occlusive diseaseK76.6Portal hypertensionK76.7Hepatorenal syndromeIHD Provided: Quan ICD10 Charlson Renal Disease 2018-08 [ICD-10 Diagnosis]CodeDescriptionI12.0Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal diseaseI13.10Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney diseaseI13.11Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal diseaseN03.2Chronic nephritic syndrome with diffuse membranous glomerulonephritisN03.3Chronic nephritic syndrome with diffuse mesangial proliferative glomerulonephritisN03.4Chronic nephritic syndrome with diffuse endocapillary proliferative glomerulonephritisN03.5Chronic nephritic syndrome with diffuse mesangiocapillary glomerulonephritisN03.6Chronic nephritic syndrome with dense deposit diseaseN03.7Chronic nephritic syndrome with diffuse crescentic glomerulonephritisN05.2Unspecified nephritic syndrome with diffuse membranous glomerulonephritisN05.3Unspecified nephritic syndrome with diffuse mesangial proliferative glomerulonephritisN05.4Unspecified nephritic syndrome with diffuse endocapillary proliferative glomerulonephritisN05.5Unspecified nephritic syndrome with diffuse mesangiocapillary glomerulonephritisN05.6Unspecified nephritic syndrome with dense deposit diseaseN05.7Unspecified nephritic syndrome with diffuse crescentic glomerulonephritisN18.1Chronic kidney disease, stage 1N18.2Chronic kidney disease, stage 2 (mild)N18.3Chronic kidney disease, stage 3 (moderate)N18.4Chronic kidney disease, stage 4 (severe)N18.5Chronic kidney disease, stage 5N18.6End stage renal diseaseN18.9Chronic kidney disease, unspecifiedN19Unspecified kidney failureN25.0Renal osteodystrophyZ49.01Encounter for fitting and adjustment of extracorporeal dialysis catheterZ49.02Encounter for fitting and adjustment of peritoneal dialysis catheterZ94.0Kidney transplant statusZ99.2Dependence on renal dialysisIHD Provided: Quan ICD9 Charlson AIDS 2018-08 [ICD-9 Diagnosis]CodeDescription042Human immunodeficiency virus [HIV] diseaseIHD Provided: Quan ICD9 Charlson Chronic Pulmonary Disease 2018-08 [ICD-9 Diagnosis]CodeDescription416.8Other chronic pulmonary heart diseases416.9Chronic pulmonary heart disease, unspecified490Bronchitis, not specified as acute or chronic491.0Simple chronic bronchitis491.1Mucopurulent chronic bronchitis491.20Obstructive chronic bronchitis without exacerbation491.21Obstructive chronic bronchitis with (acute) exacerbation491.22Obstructive chronic bronchitis with acute bronchitis491.8Other chronic bronchitis491.9Unspecified chronic bronchitis492.0Emphysematous bleb492.8Other emphysema493.00Extrinsic asthma, unspecified493.01Extrinsic asthma with status asthmaticus493.02Extrinsic asthma with (acute) exacerbation493.10Intrinsic asthma, unspecified493.11Intrinsic asthma with status asthmaticus493.12Intrinsic asthma with (acute) exacerbation493.20Chronic obstructive asthma, unspecified493.21Chronic obstructive asthma with status asthmaticus493.22Chronic obstructive asthma with (acute) exacerbation493.81Exercise induced bronchospasm493.82Cough variant asthma493.90Asthma, unspecified type, unspecified493.91Asthma, unspecified type, with status asthmaticus493.92Asthma, unspecified type, with (acute) exacerbation494.0Bronchiectasis without acute exacerbation494.1Bronchiectasis with acute exacerbation495.0Farmers' lung495.1Bagassosis495.2Bird-fanciers' lung495.3Suberosis495.4Malt workers' lung495.5Mushroom workers' lung495.6Maple bark-strippers' lung495.7"Ventilation" pneumonitis495.8Other specified allergic alveolitis and pneumonitis495.9Unspecified allergic alveolitis and pneumonitis496Chronic airway obstruction, not elsewhere classified500Coal workers' pneumoconiosis501Asbestosis502Pneumoconiosis due to other silica or silicates503Pneumoconiosis due to other inorganic dust504Pneumonopathy due to inhalation of other dust505Pneumoconiosis, unspecified506.4Chronic respiratory conditions due to fumes and vapors508.1Chronic and other pulmonary manifestations due to radiation508.8Respiratory conditions due to other specified external agentsIHD Provided: Quan ICD9 Charlson Congestive Heart Failure 2018-08 [ICD-9 Diagnosis]CodeDescription398.91Rheumatic heart failure (congestive)402.01Malignant hypertensive heart disease with heart failure402.11Benign hypertensive heart disease with heart failure402.91Unspecified hypertensive heart disease with heart failure404.01Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified404.03Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage V or end stage renal disease404.11Hypertensive heart and chronic kidney disease, benign, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified404.13Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease stage V or end stage renal disease404.91Hypertensive heart and chronic kidney disease, unspecified, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified404.93Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end stage renal disease425.4Other primary cardiomyopathies425.5Alcoholic cardiomyopathy425.7Nutritional and metabolic cardiomyopathy425.8Cardiomyopathy in other diseases classified elsewhere425.9Secondary cardiomyopathy, unspecified428.0Congestive heart failure, unspecified428.1Left heart failure428.20Systolic heart failure, unspecified428.21Acute systolic heart failure428.22Chronic systolic heart failure428.23Acute on chronic systolic heart failure428.30Diastolic heart failure, unspecified428.31Acute diastolic heart failure428.32Chronic diastolic heart failure428.33Acute on chronic diastolic heart failure428.40Combined systolic and diastolic heart failure, unspecified428.41Acute combined systolic and diastolic heart failure428.42Chronic combined systolic and diastolic heart failure428.43Acute on chronic combined systolic and diastolic heart failure428.9Heart failure, unspecifiedIHD Provided: Quan ICD9 Charlson Dementia 2018-08 [ICD-9 Diagnosis]CodeDescription290.0Senile dementia, uncomplicated290.10Presenile dementia, uncomplicated290.11Presenile dementia with delirium290.12Presenile dementia with delusional features290.13Presenile dementia with depressive features290.20Senile dementia with delusional features290.21Senile dementia with depressive features290.3Senile dementia with delirium290.40Vascular dementia, uncomplicated290.41Vascular dementia, with delirium290.42Vascular dementia, with delusions290.43Vascular dementia, with depressed mood290.8Other specified senile psychotic conditions290.9Unspecified senile psychotic condition294.10Dementia in conditions classified elsewhere without behavioral disturbance294.11Dementia in conditions classified elsewhere with behavioral disturbance331.2Senile degeneration of brainIHD Provided: Quan ICD9 Charlson Diabetes with CC 2018-08 [ICD-9 Diagnosis]CodeDescription250.40Diabetes with renal manifestations, type II or unspecified type, not stated as uncontrolled250.41Diabetes with renal manifestations, type I [juvenile type], not stated as uncontrolled250.42Diabetes with renal manifestations, type II or unspecified type, uncontrolled250.43Diabetes with renal manifestations, type I [juvenile type], uncontrolled250.50Diabetes with ophthalmic manifestations, type II or unspecified type, not stated as uncontrolled250.51Diabetes with ophthalmic manifestations, type I [juvenile type], not stated as uncontrolled250.52Diabetes with ophthalmic manifestations, type II or unspecified type, uncontrolled250.53Diabetes with ophthalmic manifestations, type I [juvenile type], uncontrolled250.60Diabetes with neurological manifestations, type II or unspecified type, not stated as uncontrolled250.61Diabetes with neurological manifestations, type I [juvenile type], not stated as uncontrolled250.62Diabetes with neurological manifestations, type II or unspecified type, uncontrolled250.63Diabetes with neurological manifestations, type I [juvenile type], uncontrolled250.70Diabetes with peripheral circulatory disorders, type II or unspecified type, not stated as uncontrolled250.71Diabetes with peripheral circulatory disorders, type I [juvenile type], not stated as uncontrolled250.72Diabetes with peripheral circulatory disorders, type II or unspecified type, uncontrolled250.73Diabetes with peripheral circulatory disorders, type I [juvenile type], uncontrolledIHD Provided: Quan ICD9 Charlson Hemiplegia or Paraplegia 2018-08 [ICD-9 Diagnosis]CodeDescription334.1Hereditary spastic paraplegia342.00Flaccid hemiplegia and hemiparesis affecting unspecified side342.01Flaccid hemiplegia and hemiparesis affecting dominant side342.02Flaccid hemiplegia and hemiparesis affecting nondominant side342.10Spastic hemiplegia and hemiparesis affecting unspecified side342.11Spastic hemiplegia and hemiparesis affecting dominant side342.12Spastic hemiplegia and hemiparesis affecting nondominant side342.80Other specified hemiplegia and hemiparesis affecting unspecified side342.81Other specified hemiplegia and hemiparesis affecting dominant side342.82Other specified hemiplegia and hemiparesis affecting nondominant side342.90Hemiplegia, unspecified, affecting unspecified side342.91Hemiplegia, unspecified, affecting dominant side342.92Hemiplegia, unspecified, affecting nondominant side343.0Congenital diplegia343.1Congenital hemiplegia343.2Congenital quadriplegia343.3Congenital monoplegia343.4Infantile hemiplegia343.8Other specified infantile cerebral palsy343.9Infantile cerebral palsy, unspecified344.00Quadriplegia, unspecified344.01Quadriplegia, C1-C4, complete344.02Quadriplegia, C1-C4, incomplete344.03Quadriplegia, C5-C7, complete344.04Quadriplegia, C5-C7, incomplete344.09Other quadriplegia344.1Paraplegia344.2Diplegia of upper limbs344.30Monoplegia of lower limb affecting unspecified side344.31Monoplegia of lower limb affecting dominant side344.32Monoplegia of lower limb affecting nondominant side344.40Monoplegia of upper limb affecting unspecified side344.41Monoplegia of upper limb affecting dominant side344.42Monoplegia of upper limb affecting nondominant sde344.5Unspecified monoplegia344.60Cauda equina syndrome without mention of neurogenic bladder344.61Cauda equina syndrome with neurogenic bladder344.9Paralysis, unspecifiedIHD Provided: Quan ICD9 Charlson Metastatic Solid Tumor 2018-08 [ICD-9 Diagnosis]CodeDescription196.0Secondary and unspecified malignant neoplasm of lymph nodes of head, face, and neck196.1Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes196.2Secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes196.3Secondary and unspecified malignant neoplasm of lymph nodes of axilla and upper limb196.5Secondary and unspecified malignant neoplasm of lymph nodes of inguinal region and lower limb196.6Secondary and unspecified malignant neoplasm of intrapelvic lymph nodes196.8Secondary and unspecified malignant neoplasm of lymph nodes of multiple sites196.9Secondary and unspecified malignant neoplasm of lymph nodes, site unspecified197.0Secondary malignant neoplasm of lung197.1Secondary malignant neoplasm of mediastinum197.2Secondary malignant neoplasm of pleura197.3Secondary malignant neoplasm of other respiratory organs197.4Secondary malignant neoplasm of small intestine including duodenum197.5Secondary malignant neoplasm of large intestine and rectum197.6Secondary malignant neoplasm of retroperitoneum and peritoneum197.7Malignant neoplasm of liver, secondary197.8Secondary malignant neoplasm of other digestive organs and spleen198.0Secondary malignant neoplasm of kidney198.1Secondary malignant neoplasm of other urinary organs198.2Secondary malignant neoplasm of skin198.3Secondary malignant neoplasm of brain and spinal cord198.4Secondary malignant neoplasm of other parts of nervous system198.5Secondary malignant neoplasm of bone and bone marrow198.6Secondary malignant neoplasm of ovary198.7Secondary malignant neoplasm of adrenal gland198.81Secondary malignant neoplasm of breast198.82Secondary malignant neoplasm of genital organs198.89Secondary malignant neoplasm of other specified sites199.0Disseminated malignant neoplasm without specification of site199.1Other malignant neoplasm without specification of site199.2Malignant neoplasm associated with transplant organIHD Provided: Quan ICD9 Charlson Mild Liver Disease 2018-08 [ICD-9 Diagnosis]CodeDescription070.22Chronic viral hepatitis B with hepatic coma without hepatitis delta070.23Chronic viral hepatitis B with hepatic coma with hepatitis delta070.32Chronic viral hepatitis B without mention of hepatic coma without mention of hepatitis delta070.33Chronic viral hepatitis B without mention of hepatic coma with hepatitis delta070.44Chronic hepatitis C with hepatic coma070.54Chronic hepatitis C without mention of hepatic coma070.6Unspecified viral hepatitis with hepatic coma070.9Unspecified viral hepatitis without mention of hepatic coma570Acute and subacute necrosis of liver571.0Alcoholic fatty liver571.1Acute alcoholic hepatitis571.2Alcoholic cirrhosis of liver571.3Alcoholic liver damage, unspecified571.40Chronic hepatitis, unspecified571.41Chronic persistent hepatitis571.42Autoimmune hepatitis571.49Other chronic hepatitis571.5Cirrhosis of liver without mention of alcohol571.6Biliary cirrhosis571.8Other chronic nonalcoholic liver disease571.9Unspecified chronic liver disease without mention of alcohol573.3Hepatitis, unspecified573.4Hepatic infarction573.8Other specified disorders of liver573.9Unspecified disorder of liverV42.7Liver replaced by transplantIHD Provided: Quan ICD9 Charlson Mod Sev Liver Disease 2018-08 [ICD-9 Diagnosis]CodeDescription456.0Esophageal varices with bleeding456.1Esophageal varices without mention of bleeding456.20Esophageal varices in diseases classified elsewhere, with bleeding456.21Esophageal varices in diseases classified elsewhere, without mention of bleeding572.2Hepatic encephalopathy572.3Portal hypertension572.4Hepatorenal syndrome572.8Other sequelae of chronic liver diseaseIHD Provided: Quan ICD9 Charlson Renal Disease 2018-08 [ICD-9 Diagnosis]CodeDescription403.01Hypertensive chronic kidney disease, malignant, with chronic kidney disease stage V or end stage renal disease403.11Hypertensive chronic kidney disease, benign, with chronic kidney disease stage V or end stage renal disease403.91Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage V or end stage renal disease404.02Hypertensive heart and chronic kidney disease, malignant, without heart failure and with chronic kidney disease stage V or end stage renal disease404.03Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage V or end stage renal disease404.12Hypertensive heart and chronic kidney disease, benign, without heart failure and with chronic kidney disease stage V or end stage renal disease404.13Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease stage V or end stage renal disease404.92Hypertensive heart and chronic kidney disease, unspecified, without heart failure and with chronic kidney disease stage V or end stage renal disease404.93Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end stage renal disease582.0Chronic glomerulonephritis with lesion of proliferative glomerulonephritis582.1Chronic glomerulonephritis with lesion of membranous glomerulonephritis582.2Chronic glomerulonephritis with lesion of membranoproliferative glomerulonephritis582.4Chronic glomerulonephritis with lesion of rapidly progressive glomerulonephritis582.81Chronic glomerulonephritis in diseases classified elsewhere582.89Chronic glomerulonephritis with other specified pathological lesion in kidney582.9Chronic glomerulonephritis with unspecified pathological lesion in kidney583.0Nephritis and nephropathy, not specified as acute or chronic, with lesion of proliferative glomerulonephritis583.1Nephritis and nephropathy, not specified as acute or chronic, with lesion of membranous glomerulonephritis583.2Nephritis and nephropathy, not specified as acute or chronic, with lesion of membranoproliferative glomerulonephritis583.4Nephritis and nephropathy, not specified as acute or chronic, with lesion of rapidly progressive glomerulonephritis583.6Nephritis and nephropathy, not specified as acute or chronic, with lesion of renal cortical necrosis583.7Nephritis and nephropathy, not specified as acute or chronic, with lesion of renal medullary necrosis585.1Chronic kidney disease, Stage I585.2Chronic kidney disease, Stage II (mild)585.3Chronic kidney disease, Stage III (moderate)585.4Chronic kidney disease, Stage IV (severe)585.5Chronic kidney disease, Stage V585.6End stage renal disease585.9Chronic kidney disease, unspecified586Renal failure, unspecified588.0Renal osteodystrophyV42.0Kidney replaced by transplantV45.1RENAL DIALYSIS STATUSV45.11Renal dialysis statusV45.12Noncompliance with renal dialysisV56.0Encounter for extracorporeal dialysisV56.1Fitting and adjustment of extracorporeal dialysis catheterV56.2Fitting and adjustment of peritoneal dialysis catheterV56.31Encounter for adequacy testing for hemodialysisV56.32Encounter for adequacy testing for peritoneal dialysisV56.8Encounter for other dialysisIHD Provided: Quan ICD9 Charlson Rheumatologic Disease 2018-08 [ICD-9 Diagnosis]CodeDescription446.5Giant cell arteritis710.0Systemic lupus erythematosus710.1Systemic sclerosis710.2Sicca syndrome710.3Dermatomyositis710.4Polymyositis714.0Rheumatoid arthritis714.1Felty's syndrome714.2Other rheumatoid arthritis with visceral or systemic involvement714.81Rheumatoid lung714.89Other specified inflammatory polyarthropathies725Polymyalgia rheumaticaTable B. Healthcare Common Procedure Coding System (HCPCS) Codes and National Drug Codes (NDC) for DLBCL Treatment per NCCN GuidelinesAgentHCPCS CodesNDC CodesBendamustine HCl C9243, J9033, J903463459034804, 63459039008, 63459039120, 63459039502, 63459039602BevacizumabC9214, C9257, J9035, Q2024, S0116BleomycinC9417, J904000013161678, 00013163686, 00015301020, 00015301026, 00015306301, 00015306326, 00074161601, 00074163601, 00703315401, 00703315491, 00703315501, 00703315591, 55390000501, 55390000601, 61703032322, 61703033218, 63323013610, 63323013720, 70121156701Brentuximab vedotinC9287, J904251144005001CarboplatinJ904500015321030, 00015321130, 00015321176, 00015321230, 00015321329, 00015321330, 00015321429, 00015321430, 00015321529, 00015321530, 00015321630, 00015323011, 00015323111, 00015323211, 00015323311, 00409112910, 00409112911, 00409112912, 00591221911, 00591222011, 00591333626, 00591333712, 00591333889, 00591345460, 00591368711, 00703324411, 00703324611, 00703324811, 00703324911, 00703326401, 00703326601, 00703326801, 00703326871, 00703327401, 00703327601, 00703327801, 00703423901, 00703423981, 00703424401, 00703424481, 00703424601, 00703424681, 00703424801, 00703424881, 00703424891, 10019091201, 10019091202, 10019091203, 10019091501, 10019091601, 10019091701, 10139006005, 10139006015, 10139006045, 10518010110, 10518010111, 10518010112, 15210006112, 15210006312, 15210006612, 15210006712, 25021020205, 25021020215, 25021020245, 25021020251, 47335015040, 47335015140, 47335028440, 47335030040, 50111096576, 50111096676, 50111096776, 55390015001, 55390015101, 55390015201, 55390015301, 55390015401, 55390015501, 55390015601, 55390022001, 55390022101, 55390022201, 61703033918, 61703033922, 61703033950, 61703033956, 61703033961, 61703033962, 61703033963, 61703036018, 61703036022, 61703036050, 63323016610, 63323016720, 63323016721, 63323016800, 63323016905, 63323016915, 63323016945, 63323017205, 63323017215, 63323017245, 63323017260, 66758004701, 66758004702, 66758004703, 66758004704, 67457049154, 67457049215, 67457049346, 67457049461, 67457060820CisplatinJ9060, J906200003307297, 00015307020, 00015307220, 00015322022, 00015322026, 00015322122, 00015322126, 00069008101, 00069008407, 00703574711, 00703574811, 10019091001, 10019091002, 44567050901, 44567051001, 44567051101, 49452207801, 49452207802, 49452207803, 55390009901, 55390011250, 55390011299, 55390018701, 55390041450, 55390041499, 63323010351, 63323010364, 63323010365, 67457042410, 67457042551, 68001028327, 68001028332CyclophosphamideJ8530, J9070, J9080, J9090, J9091, J9092, J9093, J9094, J9095, J9096, J909700013560693, 00013561693, 00013562693, 00013563601, 00013563670, 00013564670, 00015050041, 00015050141, 00015050241, 00015050301, 00015050302, 00015050303, 00015050401, 00015050541, 00015050641, 00015053941, 00015054641, 00015054712, 00015054741, 00015054812, 00015054841, 00015054912, 00015054941, 00054038225, 00054038325, 00054412925, 00054413025, 00054808925, 00054813025, 00781323394, 00781324494, 00781325594, 10019093501, 10019093601, 10019093701, 10019093801, 10019093901, 10019094201, 10019094301, 10019094325, 10019095501, 10019095601, 10019095701, 54868500500, 54868500501, 54868521800, 54868521801, 54868521802CytarabineC9422, J9100, J911000009037301, 00009047301, 00009329501, 00009329601, 00013710678, 00069015202, 00069015302, 00069015401, 00069015501, 00364246753, 00364246854, 00469103005, 00469103025, 00469103050, 00703518203, 00703519302, 00703519401, 00703519501, 53905013110, 53905013210, 53905013301, 53905013401, 53905033101, 55390013110, 55390013210, 55390013301, 55390013401, 55390080610, 55390080710, 55390080801, 55390080901, 57457045450, 57665033101, 61703030346, 61703030350, 61703030425, 61703030436, 61703030509, 61703030538, 61703031922, 63323012020, 67457045220, 67457045450, 67457045552DocetaxelJ9170DoxorubicinC9415, J9000, J9001, J9002, Q204800013108691, 00013109691, 00013109694, 00013110679, 00013111683, 00013113691, 00013114691, 00013114694, 00013115679, 00013116683, 00013117601, 00013117687, 00013123691, 00013124691, 00013125679, 00013126683, 00013128683, 00015335122, 00015335222, 00015335322, 00069017001, 00069017101, 00069303020, 00069303120, 00069303220, 00069303320, 00069303420, 00069400405, 00069402625, 00069403001, 00069403101, 00069403201, 00069403301, 00069403401, 00074504001, 00074504303, 00074504601, 00143954601, 00143954701, 00143954801, 00143954810, 00143954901, 00143954910, 00186153013, 00186153101, 00186153231, 00186153261, 00186153281, 00186157512, 00469100161, 00469883020, 00469883030, 00469883130, 00469883250, 00702023110, 00702023206, 00702023301, 00702023510, 00702023606, 00702023610, 00702023701, 00703504001, 00703504303, 00703504601, 10019092001, 10019092102, 17314960001, 17314960002, 25021020705, 25021020725, 25021020751, 38779065206, 38779065209, 45963073355, 45963073357, 45963073360, 45963073368, 47335004940, 47335005040, 47335008250, 47335008350, 53150031410, 53150031501, 53150031701, 53150032010, 53905023110, 53905023206, 53905023210, 53905023301, 53905023510, 53905023606, 53905023610, 53905023701, 53905023801, 54868313100, 55390023110, 55390023210, 55390023301, 55390023510, 55390023610, 55390023701, 55390023801, 55390024110, 55390024210, 55390024301, 55390024510, 55390024610, 55390024701, 55390024801, 58406051101, 59676096001, 59676096002, 61471029512, 62756082640, 62756082740, 63323010161, 63323088305, 63323088310, 63323088330, 67457039354, 67457039410, 67457039525, 67457039610, 67457043650, 67457047810EtoposideC9414, C9425, J8560, J9181, J918200013733691, 00013734694, 00013735688, 00013736673, 00015306120, 00015306124,00015306220, 00015306224, 00015308420, 00015309145, 00015309520, 00015309530, 00015309595, 00015340420, 00074148501, 00074148502, 00074148503, 00186157131, 00364302853, 00378326694, 00703564301, 00703564601, 00703565301, 00703565601, 00703565691, 00703565701, 00703565791, 00703565801, 00703566701, 00703566801, 10019093001, 10019093002, 16729011408, 16729011411, 16729011431, 16729026231, 51079096505, 53905029101, 55390029101, 55390029201, 55390029301, 55390049101, 55390049201, 55390049301, 58406071112, 58406071418, 63323010405, 63323010425, 63323010450, 68001026525, 68001026526, 68001026527Gemcitabine HClJ920100002750101, 00002750201, 00069385710, 00069385810, 00069385910, 00409008701, 00409018101, 00409018125, 00409018201, 00409018225, 00409018301, 00409018325, 00409018501, 00409018601, 00409018701, 00591356279, 00591356355, 00703577501, 00703577801, 00781328275, 00781328379, 16729009203, 16729011711, 16729011838, 23155021331, 23155048331, 25021020810, 25021020950, 25021023410, 25021023550, 45963061257, 45963061959, 45963062060, 45963062357, 45963062458, 45963063660, 47335015340, 47335015440, 55111068607, 55111068725, 55390039110, 55390039150, 63323010210, 63323010213, 63323010294, 63323012550, 63323012553, 63323012600, 67457046201, 67457046302, 67457046420, 68001028225, 68001028226, 68001028227IfosfamideC9427, J920800015055605, 00015055641, 00015055741, 00015355427, 00015355626, 00015356415, 00069449522, 00069449622, 00338399101, 00338399301, 00703342711, 00703342911, 00703410048, 00703410058, 00703410068, 00703410948, 00703410958, 00703410968, 10019092501, 10019092582, 10019092602, 10019092616, 63323014210, 63323014212, 63323017420, 63323017460, 67457042920, 67457044360, 67457060920Lenalidomide59572040200, 59572040228, 59572040500, 59572040528, 59572040530, 59572041000, 59572041028, 59572041030, 59572041500, 59572041521, 59572042000, 59572042021, 59572042500, 59572042521, 59572042525MesnaC9428, J920900015355427, 00015355626, 00015355841, 00015355941, 00015356041, 00015356141, 00015356241, 00015356302, 00015356303, 00015356310, 00015356311, 00015356415, 00015356512, 00338130501, 00338130503, 00703410048, 00703410058, 00703410068, 00703410948, 00703410958, 00703410968, 00703480501, 00703480503, 10019095301, 10019095302, 25021020110, 25021020111, 25021020166, 25021020167, 25021020168, 25021020169, 55390004501, 55390026601, 55390034701, 63323073310, 63323073311, 63323073312, 67108356509, 67457014810MethotrexateJ8610, J9250, J926000005450704, 00005450705, 00005450707, 00005450709, 00005450723, 00005450791, 00013226691, 00013227691, 00013228691, 00013229691, 00054455015, 00054455025, 00054855003, 00054855005, 00054855006, 00054855007, 00054855010, 00054855025, 00069014602, 00069014702, 00069014801, 00069014901, 00069018102, 00069020410, 00182153901, 00182153995, 00205455626, 00205465302, 00205465490, 00205532526, 00205532618, 00205532730, 00205533734, 00205533798, 00205533834, 00205933792, 00247222200, 00247222230, 00247222260, 00364249901, 00364249936, 00378001401, 00378001450, 00405464301, 00405464336, 00536399801, 00536399836, 00555057202, 00555057235, 00555057245, 00555057246, 00555057247, 00555057248, 00555057249, 00555092701, 00555092801, 00555092901, 00555094501, 00603449921, 00677161001, 00703367103, 00703367193, 00703367301, 00703367501, 00703367591, 00703367801, 00703367881, 00781107601, 00781107636, 00839790506, 00904174960, 00904174973, 00904601260, 10019094001, 10019094002, 10019094101, 10139006202, 10139006210, 10139006240, 11845110401, 16729027703, 16729027730, 16729027735, 21695011100, 23490588900, 38779003506, 42291059401, 43063043930, 49349031402, 49452460101, 49452460102, 49452460103, 49452460104, 49999038024, 49999038036, 51079067005, 51079067086, 51079067087, 51079067088, 51079067089, 51285036601, 51285036701, 51285036801, 51285036901, 51285050902, 52959024400, 53905003110, 53905003210, 53905003310, 53905003410, 54436001004, 54436001204, 54436001504, 54436001704, 54436002004, 54436002204, 54436002504, 54436007504, 54569181800, 54569181804, 54569181805, 54569181806, 54569181807, 54569181808, 54569181809, 54569498300, 54868017300, 54868017301, 54868382600, 54868382601, 54868382602, 54868382603, 54868382604, 54868382605, 54868382606, 54868382607, 54868471600, 54868479600, 54868480900, 55289092430, 55390003110, 55390003210, 55390003310, 55390003410, 55390014301, 55887007301, 58406067101, 58406067103, 58406067105, 58406067301, 58406068114, 58406068117, 58406068312, 58406068315, 58406068316, 58406068318, 59137050504, 59137051004, 59137051504, 59137052004, 59137052504, 59137053004, 59137053504, 59137054004, 59137054504, 59137055004, 59911587401, 60429008036, 61703035010, 61703035038, 61703040707, 61703040732, 61703040804, 61703040807, 61703040813, 61703040822, 61703040825, 61703040832, 61703040841, 61703040858, 63323012102, 63323012104, 63323012108, 63323012110, 63323012140, 63323012250, 63323012259, 63323012302, 63323012310, 63629147201, 66479013501, 66479013509, 66479013611, 66479013613, 66479013619, 66479013721, 66479013929, 66758004002, 66758004008, 66758004101, 67253032010, 67253032036, 67253058042, 67253058043, 67253058044, 67253058045, 67253058046, 67457022102, 67457022110, 67457022140, 67457046610, 67457046799, 67457048040, 67457048599, 67457048699, 68115063200Mitoxantrone HClJ929300205939336, 00205939372, 00703468001, 00703468091, 00703468501, 00703468591, 00703468601, 00703468691, 10518010510, 10518010511, 10518010512, 15210040335, 44087152001, 44087152501, 44087153001, 55390008301, 55390008401, 55390008501, 58406064003, 58406064005, 58406064007, 61703034318, 61703034365, 61703034366, 63323013210, 63323013212, 63323013215OxaliplatinC9205, J926300024059010, 00024059120, 00024059240, 00024059602, 00024059704, 00069006701, 00069007001, 00069007201, 00069007401, 00069101001, 00703398501, 00703398601, 00781331570, 00781331780, 00955102720, 00955172510, 00955172720, 00955173110, 00955173320, 25021021120, 25021021250, 25021023310, 25021023320, 41616017640, 41616017840, 45963061153, 45963061159, 47335004640, 47335004740, 47335017640, 47335017840, 61703036318, 61703036322, 61703036330, 61703036331, 61703036332, 61703036340, 63323017530, 63323017650, 63323021110, 63323021220, 63323065010, 63323065017, 63323065020, 63323065027, 63323075010, 63323075020, 66758005301, 66758005302, 67457044220, 67457046910, 67457047610PaclitaxelC9127, J9265, J9267PemetrexedC9213, J9305Procarbazine HClS018200004005301, 54482005301, 54868136600RituximabJ931050242005121, 50242005306VinblastineJ9360VincristineJ9370, J9375, J938000002719401, 00002719501, 00002719601, 00002719801, 00002719809, 00002719901, 00002719909, 00013745686, 00013746686, 00364244851, 00364244852, 00402102801, 00402102802, 00409030926, 00703440211, 00703441211, 20536032201, 49452811401, 61703030906, 61703030916, 61703030925, 61703030926Vinorelbine tartrateC9440, J939000069009901, 00069010303, 00069020510, 00069020550, 00703418201, 00703418281, 00703418291, 00703418301, 00703418381, 00703418391, 10019097001, 10019097002, 25021020401, 25021020402, 25021020405, 45963060755, 45963060756, 55390006901, 55390007001, 55390026701, 55390026801, 59911595801, 59911595901, 61703034106, 61703034109, 63323014801, 63323014805, 64370021001, 64370025001, 64370308602, 66758004501, 66758004502, 67457043111, 67457047953, 67457048101Table C: Codes for HSCT (includes autologous and allogeneic transplantations)CPT-4 Procedure Codes38204, 38205, 38206, 38207, 38208, 38209, 38210, 38211, 38212, 38213, 38214, 38215, 38230, 38232, 38240, 38241, 38242ICD-9 Procedure Codes41.00, 41.01, 41.02, 41.03, 41.04, 41.05, 41.06, 41.07, 41.08References ADDIN EN.REFLIST 1.Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Medical care. 2005 Nov;43(11):1130-9. PubMed PMID: 16224307; eng.2.Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. American journal of epidemiology. 2011 Mar 15;173(6):676-82. doi: 10.1093/aje/kwq433. PubMed PMID: 21330339; eng.3.Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of chronic diseases. 1987;40(5):373-83. PubMed PMID: 3558716; eng.4.Khan NF, Perera R, Harper S, et al. Adaptation and validation of the Charlson Index for Read/OXMIS coded databases. BMC family practice. 2010 Jan 5;11:1. doi: 10.1186/1471-2296-11-1. PubMed PMID: 20051110; PubMed Central PMCID: PMCPMC2820468. eng. ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download